Integrated Bioinformatics, Environmental Epidemiologic and Genomic Approaches to Identify Environmental and Molecular Links between Endometriosis and Breast Cancer by Roy, Deodutta et al.
Florida International University
FIU Digital Commons
Departments of Biostatistics Robert Stempel College of Public Health & SocialWork
10-23-2015
Integrated Bioinformatics, Environmental
Epidemiologic and Genomic Approaches to
Identify Environmental and Molecular Links
between Endometriosis and Breast Cancer
Deodutta Roy
Department of Environmental and Occupational Health, Florida International University, Droy@fiu.edu
Marisa L. Morgan
Department of Environmental and Occupational Health, Florida International University, mmorg003@fiu.edu
Changwon Yoo
Department of Biostatistics, Florida International University, cyoo@fiu.edu
Alok Deoraj
Department of Environmental and Occupational Health, Florida International University, adeoraj@fiu.edu
Sandhya Roy
BMSNF Inc.
See next page for additional authors
Follow this and additional works at: http://digitalcommons.fiu.edu/biostatistics_fac
Part of the Biostatistics Commons, and the Medicine and Health Sciences Commons
This work is brought to you for free and open access by the Robert Stempel College of Public Health & Social Work at FIU Digital Commons. It has
been accepted for inclusion in Departments of Biostatistics by an authorized administrator of FIU Digital Commons. For more information, please
contact dcc@fiu.edu.
Recommended Citation
Roy, Deodutta; Morgan, Marisa L.; Yoo, Changwon; Deoraj, Alok; Roy, Sandhya; Yadav, Vijay Kumar; Garoub, Mohannad; Assaggaf,
Hamza; and Doke, Mayur, "Integrated Bioinformatics, Environmental Epidemiologic and Genomic Approaches to Identify
Environmental and Molecular Links between Endometriosis and Breast Cancer" (2015). Departments of Biostatistics. Paper 3.
http://digitalcommons.fiu.edu/biostatistics_fac/3
Authors
Deodutta Roy, Marisa L. Morgan, Changwon Yoo, Alok Deoraj, Sandhya Roy, Vijay Kumar Yadav, Mohannad
Garoub, Hamza Assaggaf, and Mayur Doke
This article is available at FIU Digital Commons: http://digitalcommons.fiu.edu/biostatistics_fac/3
 Int. J. Mol. Sci. 2015, 16, 25285-25322; doi:10.3390/ijms161025285 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
Integrated Bioinformatics, Environmental Epidemiologic and 
Genomic Approaches to Identify Environmental and Molecular 
Links between Endometriosis and Breast Cancer 
Deodutta Roy 1,*, Marisa Morgan 1, Changwon Yoo 2, Alok Deoraj 1, Sandhya Roy 3,  
Vijay Kumar Yadav 4, Mohannad Garoub 1, Hamza Assaggaf 1 and Mayur Doke 1 
1 Department of Environmental & Occupational Health, Florida International University,  
Miami, FL 33199, USA; E-Mails: mmorg003@fiu.edu (M.M.); adeoraj@fiu.edu (A.D.); 
mgaro005@fiu.edu (M.G.); hassagga@fiu.edu (H.A.); mdoke001@fiu.edu (M.D.) 
2 Department of Biostatistics, Robert Stempel College of Public Health and Social Work,  
Florida International University, Miami, FL 33199, USA; E-Mail: cyoo@fiu.edu 
3 BMSNF Inc., Aventura, FL 33180, USA; E-Mail: roy.sandhya09@gmail.com 
4 Department of Physics, GKPD College, Karpoorigram, Samastipur 848129, India;  
E-Mail: sundrian9@gmail.com 
* Author to whom correspondence should be addressed; E-Mail: droy@fiu.edu;  
Tel.: +1-305-348-1694; Fax: +1-305-348-4901. 
Academic Editor: Paul B. Tchounwou 
Received: 18 August 2015 / Accepted: 12 October 2015 / Published: 23 October 2015 
 
Abstract: We present a combined environmental epidemiologic, genomic, and bioinformatics 
approach to identify: exposure of environmental chemicals with estrogenic activity; 
epidemiologic association between endocrine disrupting chemical (EDC) and health effects, 
such as, breast cancer or endometriosis; and gene-EDC interactions and disease associations. 
Human exposure measurement and modeling confirmed estrogenic activity of three selected 
class of environmental chemicals, polychlorinated biphenyls (PCBs), bisphenols (BPs),  
and phthalates. Meta-analysis showed that PCBs exposure, not Bisphenol A (BPA) and 
phthalates, increased the summary odds ratio for breast cancer and endometriosis. 
Bioinformatics analysis of gene-EDC interactions and disease associations identified several 
hundred genes that were altered by exposure to PCBs, phthalate or BPA. EDCs-modified 
genes in breast neoplasms and endometriosis are part of steroid hormone signaling and 
inflammation pathways. All three EDCs–PCB 153, phthalates, and BPA influenced five 
common genes—CYP19A1, EGFR, ESR2, FOS, and IGF1—in breast cancer as well as in 
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endometriosis. These genes are environmentally and estrogen responsive, altered in human 
breast and uterine tumors and endometriosis lesions, and part of Mitogen Activated Protein 
Kinase (MAPK) signaling pathways in cancer. Our findings suggest that breast cancer and 
endometriosis share some common environmental and molecular risk factors. 
Keywords: bioinformatics; breast cancer; bisphenol A; endocrine disruptors; endometriosis; 
genomics; PCBs; phthalates 
 
1. Introduction 
Breast cancer and endometriosis are multifactorial complex chronic diseases with both genetic and 
environmental contributors. Many environmental and molecular risk factors common to breast cancer 
and endometriosis have received insufficient attention in molecular epidemiologic investigations 
because these studies have reported inconsistent results of an association with these contributors. Both 
breast cancer and endometriosis have in common one of the etiological factors, i.e., estrogen [1]. 
Unopposed estrogen stimulates the growth of endometrial cells in the uterus as well as proliferation of 
breast cells. Tamoxifen, a hormonal therapy for breast cancer, stimulates the growth of endometrial  
cells and can cause endometriosis [2]. Altered endogenous estrogen is linked with an increased risk  
of endometriosis and breast cancer among postmenopausal women [3–5]. Recently, a new report by  
the United Nations Environment Programme (UNEP) and World Health Organization (WHO) entitled 
“State of the Science: Endocrine Disrupting Chemicals-2012” highlighted that approximately 800 
chemicals are suspected to act as endocrine disruptors (EDs) or mimic natural hormones or disrupt 
hormone regulation [6,7]. Some of these EDs mimic natural or synthetic estrogen. This recent UNO 
report has renewed the concern by highlighting that there may be some associations between exposure 
to estrogen-mimicking EDs and an increased risk of breast cancer in women [6,7]. The estrogen 
mimicking EDs include a variety of chemicals such as pesticides, fungicides, industrial compounds,  
by-products of industrial processes, and chemicals used in the manufacturing of plastics. Indeed the 
estrogen-mimicking EDs that are persistent in the environment, highly lipophilic, and they readily  
bio-accumulate and magnify within the food chain [4–7]. Many of these chemicals are used in a variety 
of consumer products; therefore exposure to endocrine disrupting chemicals (EDCs) among the general 
population is widespread. Human exposure to EDCs may result from inhalation through the air, 
absorption through the skin, and most commonly through the ingestion of contaminated food and  
water [8,9]. EDCs may produce a wide range of adverse effects because of the complexity of the 
endocrine system with its multiple signaling pathways, feedback mechanisms and cross-talks. Although 
a number of experimental animal studies have shown that many chemicals have potential endocrine 
disrupting activities, the data, however, on their endocrine disrupting effects in humans is limited. The 
role of EDC’s in the etiology of some of the human cancers and reproductive health hazards has been 
implicated, although the linkage between these two processes is highly controversial [8]. In addition to 
their endocrine disrupting effects, some environmental estrogen-like chemicals produce multiple genetic 
and/or non-genetic hits, which may contribute to the induction of genomic instability in stem cells [4]. 
In the last decade, exposure to multiple EDCs such as polychlorinated biphenyls (PCBs), phthalates, and 
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bisphenol A (BPA) have been detected in >90% of blood and urine samples collected [8,10–12]. PCBs 
have been shown to interfere with reproductive function and development in animals and humans by 
either increasing or blocking estrogen activity [4–7]. Adverse reproductive health effects have been 
established in a number of animal studies that linked PCB exposures to decreased sperm fertilizing 
ability in mice [13], changes in the uterine myometrium and gland formation in mice [14], and a 
significant dose-dependent relationship in the prevalence and severity of endometriosis in rhesus 
monkeys [15]. Among phthalates, di-(2-ethylhexyl) phthalate (DEHP), di-butyl phthalate (DBP) and 
butylbenzylphthalate (BBP) have been studied for their endocrine disrupting effects. Phthalates have  
been shown to produce anti-androgenic effects by suppressing testosterone and estrogen production. 
Exposure to high levels of phthalate have been reported to result in reproductive abnormalities in  
female rodents that included increased uterine and ovarian weights and malformations, delayed onset  
of puberty; and modified morphology of the mammary gland [16]. The majority of human exposure to  
BPA is via ingestion of contaminated food products [4,9]. We have shown that BPA is oxidized to 
bisphenol-o-quinone by cytochrome P450 activation system. Administration of a single dose or multiple 
doses of 200 mg/kg of BPA to CD1 male rats produces in vivo DNA adducts matching the profile of 
dGMP-bis-phenol-o-quinone. Covalent modifications in DNA by in vivo exposure of BPA are suspected 
to be a factor in the induction of endocrine toxicity [17]. In rodent females, BPA exposure has been shown 
to cause alterations in both development and gene expression of the mammary gland, cystic ovaries, 
endometrial hyperplasia, adenomyosis, leiomyomas, atypical hyperplasia, stromal polyps, ductal 
hyperplasia and carcinoma, a decline in fertility and fecundity, decreased wet weight of the vagina, 
decreased volume of the endometrial lamina propria, and an increased expression of estrogen  
receptor-α (ERα) and progesterone receptors [17–23]. Based on this body of evidence, we postulate that 
exposure to EDCs during early development of the breast, endometrium, and prostate may not only 
alter their development, but also contribute to increased susceptibility to complex chronic diseases 
via chemical-induced effects on stem cells. 
There is a general agreement that human populations are constantly exposed to a wide variety of 
environmental estrogen-like chemicals. We are beginning to acknowledge endocrine disrupting effects 
of these chemicals in humans through experimental animal data and epidemiological studies [6,7].  
Only a limited number of EDCs, such as diethylstilbestrol (DES), BPA, PCBs, phthalates and 
dichlorodiphenyltrichloroethane (DDT), have been studied extensively to assess the endocrine disrupting 
effects in experimental models and in humans. Through research on hormonal contraception, postmenopausal 
hormonal therapies and estrogen-receptor (ER)-based endocrine therapies, we know that estrogens are a 
major risk factor of both breast cancer and endometriosis [1–3]. The proven contribution of unopposed 
estrogens to the risk for breast cancer, endometriosis or endometrial neoplasia have further renewed 
health concerns about estrogen mimicking EDCs found in food, personal care products or as environmental 
contaminants. PCBs, BPA, and phthalates are the most extensively studied EDCs, and therefore, this 
article is focused mainly on analyzing the molecular risk factors of breast cancer and endometriosis in 
association with exposure of these three selected classes of EDCs–PCBs, BPA, and phthalates. 
While there are studies which link EDCs–PCBs, BPA, and phthalate exposure to an increased risk  
of breast cancer or endometriosis, there have also been inconsistent study findings with reports  
of no association. In this study, we used a combined environmental epidemiologic, genomic, and 
bioinformatics approach to understand the relationship between EDCs and risk of developing  
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estrogen-dependent breast cancer and endometriosis, by examining interactions between genes, diseases  
and these three selected classes of EDCs. We also evaluated the possibility that “estrogen mimicking 
endocrine disruptor responsive genes” are potentially associated with systemic changes in the etiology of 
breast cancer and endometriosis. Here we used a comprehensive approach to integrate bioinformatics, 
genomics, environmental and epidemiologic data to identify (1) genes that interact with three classes of 
EDCs; and (2) molecular pathways that are potentially influenced by EDC exposures that potentially links 
with the development of breast cancer and/or endometriosis (Figure 1). The first and second steps in our 
method included modeling to assess estrogenicity of environmental chemicals to identify the potential 
for endocrine disruption and assessing association between EDC exposure and diseases, respectively. 
The third step included identifying responsive genes to EDC exposures using the Comparative Toxicology 
Database (CTD), Environmental Genome Project and Kyoto Encyclopedia of Genes and Genomes 
(KEGG). These EDC responsive genes were then compared to a curated list of genes in breast cancer 
and endometriosis. This comparison produced a list of genes responsive to the environment and 
important to breast cancer and endometriosis that was then further analyzed using gene networking tools 
such as RSpider, Cytoscape, and DAVID. Using this comprehensive approach to integrate bioinformatics, 
genomics, environmental and epidemiologic data, we were able to identify environmentally responsive 
genes that are potentially involved in interactions with EDCs and may be significant for the development 
of breast cancer and endometriosis. Potential gene-EDCs interactions may help generate novel hypotheses 
to further evaluate the biological-based mechanisms and better understand the significant impact that EDC 
exposures have on the etiology of breast cancer and endometriosis. 
 
Figure 1. The flow chart shows the steps involved in assessing human exposure and health 
effects of endocrine disrupting chemicals, and identifying the molecular link between 
endometriosis and breast cancer based on environmental response on epidemiologic, 
genomics, and bioinformatics databases. 
2. Results 
2.1. Human Exposure Measurement and Modeling 
First, we searched the EDCs-gene associations in CTD which revealed that the most common studied 
EDCs for gene interaction were bisphenol A, bisphenol A-glycidyl methacrylate, dibutyl phthalate, 
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diethylhexyl Phthalate; and PCB congeners—3,4,3′,4′-tetrachlorobiphenyl (77), 2′,3,3′,4′,5-pentachloro-
4-hydroxybiphenyl (4′-OH-PCB-86), 3,4,5,3′,4′-pentachlorobiphenyl (126), 2,3,3′,4,4′,5-hexachlorobiphenyl 
(153), and 2,2′,3,4,4′,5,5′-heptachlorobiphenyl (180). We used these EDCs to assess their estrogenic 
activity. A number of exposure models have been proposed for EDCs. We mapped these chemicals onto 
the KEGG endocrine disrupting compound, the KEGG pathway and metabolic pathways, particularly 
synthetic and degradation pathways of EDCs, CTD based analysis of estrogen receptor signaling 
pathway genes, and Endocrine Disruptor Knowledge Base (EDKB) computational models. These 
genomic web based tools predicted estrogenic activity of all EDCs, except bisphenol a-glycidyl 
methacrylate and was consistent with the previous reports [4–7]. Bisphenol a-glycidyl methacrylate was 
not active. 
2.2. Meta-Analysis of Association between Exposure to EDCs and Risk of Breast Cancer and Endometriosis 
Here we reviewed and meta-analyzed environmental epidemiologic evidence for the risk of breast 
cancer with exposure to EDCs-PCB, phthalates, and BPA. 
2.2.1. PCBs and Breast Cancer 
Of the 125 publications we identified in our search, we based our meta-analysis on evidence from  
23 selected publications of epidemiological studies which we categorized by outcome: breast cancer  
and endometriosis. The measure of exposure varied slightly between studies. PCB concentrations were 
measured in serum (n = 154) or plasma (n = 2), phthalate concentrations were measured in urine  
(n = 3) or plasma (n = 1), and BPA concentrations were measured in urine (n = 1) or blood (n = 1). All 
of the selected studies calculated unadjusted and/or adjusted arithmetic means, geometric means, 
medians, or mean TEQ/kg values to assess and compare EDC exposure among cases and controls. 
Furthermore, all of the studies estimated ORs and 95% CIs for breast cancer and endometriosis using 
unadjusted and/or adjusted logistic regression models. We identified twelve epidemiologic studies 
related to PCB, phthalate, or BPA exposure and breast cancer. Ten of the twelve studies assessed the 
relationship between PCB exposure and breast cancer [24–34], one study assessed the relationship 
between phthalate exposure and breast cancer [35], and one study assessed the relationship between 
BPA exposure and breast cancer [36]. All twelve of the identified studies were case-control studies. In 
all of the studies, cases had histologically confirmed breast cancer and controls had no history of breast 
cancer diagnosis. In the majority of the studies, controls were matched on age and residence. 
All ten of the studies that addressed the relationship between PCB exposure and breast cancer 
presented individual PCB congener results as well as a measure of total PCBs, the sum of individual 
congeners. To summarize the main results between PCB exposure and breast cancer, lipid adjusted arithmetic 
means or geometric means of total PCB exposure were provided for seven studies [24,27,28,31,33,34,37], 
median lipid adjusted PCB levels were provided in one study [26], and mean TEQ/kg of lipids was 
provided in one study [30]. Furthermore, all studies estimated ORs and 95% CIs for breast cancer using 
adjusted and/or unadjusted logistic regression models with eight of the ten studies using tertiles, 
quartiles, or quintiles to compare highest versus lowest exposure categories. 
Three of the ten PCB case-control studies failed to find any associations between exposure to total 
PCBs and breast cancer risk [28,29,34], while two of the ten PCB studies found an inverse association 
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between total PCB levels and breast cancer [30,32]. The largest case-control study conducted by 
Gammon et al. [27] consisted of 646 newly diagnosed breast cancer cases and 429 matched controls 
failed to find any association between PCB exposure and breast cancer risk when comparing the  
highest quintile of serum Peak-4 (nos. 118, 153, 138, and 180) PCB levels to the lowest quintile  
(OR = 0.83, 95% CI 0.54–1.29). Gatto et al. [28] did not find any associations with breast cancer when 
comparing the highest vs. lowest quintiles of mean total PCB levels in 355 cases and 327 controls  
(OR = 1.01, 95% CI 0.63–1.63) and Wolff et al. [33] did not find any associations with breast cancer 
when comparing the highest vs. lowest quartiles of serum total PCB levels in 110 cases and 213 controls. 
Itoh et al. [29] found a decreased risk of breast cancer when comparing the highest quartile of median 
total PCB levels to the lowest quartile (OR = 0.33, 95% CI 0.14–0.78) and Pavuk et al. [31] found higher 
serum PCB levels to be inversely associated with breast cancer in total PCBs (OR = 0.42, 95% CI 0.10–1.82) 
and in three sub-groups of PCBS: estrogenic, anti-estrogenic/dioxin-like, and phenobarbital-type. 
Five of the PCB case-control studies found significant associations between breast cancer and  
exposure to individual PCB congeners, total PCBs, or specific sub-groups of PCBs [24,25].  
Charlier et al. [24] measured mean levels of seven PCB congeners in 60 breast cancer cases and  
60 healthy controls. They found that total PCBs to be significantly different (p = 0.012) between cases  
(7.08 ppb) and controls (5.10 ppb) and significantly higher serum levels of PCB 153 in breast cancer 
cases when compared to controls (1.63 vs. 0.63 ppb, p < 0.0001). The OR of breast cancer for PCB  
153 was 1.8 (95% CI 1.4–2.5). In a nested, matched case-control study of 112 cases and controls,  
Cohn et al. [25] did not find any associations for total PCBs or PCB groupings, however, a significant 
association was found for PCB 203 when comparing the highest vs. lowest quartiles of exposure  
(OR = 6.3, 95% CI 1.9–21.7). In a matched case-control study of 314 cases and 523 controls,  
Demers et al. [26] found breast cancer risk significantly associated with the sum of mono-ortho 
congeners (nos. 105, 118, 156) (OR = 2.02, 95% CI 1.24–3.28), PCB 118 (OR = 1.60, 95% CI 1.01–2.53) 
and PCB 156 (OR = 1.80, 95% CI 1.11–2.94) when comparing the fourth vs. first quartiles. In a  
population based case-control study with sub-groups of African-American women and white women, 
Millikan et al. [35] did not find any associations with total PCBs and breast cancer among all participants 
(OR = 1.09, 95% CI 0.79–1.52) or white women (OR = 1.03, 95% CI 0.68–1.56), but did find a slightly 
elevated risk for African-American women (OR = 1.74, 95% CI 1.00–3.01). Recio-Vega et al. [32] 
found the GM of total PCBs to be significantly higher in cases than controls (5.26 vs. 3.33 ppb)  
(OR = 1.09, 95% CI 1.01–1.14) as well as an increased risk of breast cancer among PCBs grouped by 
structure-activity relationships and eight individual PCB congeners (nos. 118, 128, 138, 170, 180, 195, 
206, and 209). 
Since the relationship between PCB exposure and breast cancer in ten epidemiologic studies was 
inconsistent or conflicting, risk estimates of PCBs on breast cancer from six case control studies were 
extracted and summarized using meta-analytic methods. Combining six studies of exposure to PCBs 
produced a summary risk estimate of 1.33 (95% CI: 0.72–2.65) (Table 1; Figure 2). However, PCB 
exposures were found to be associated with development of breast cancer as a meta-analysis of six 
studies produced an increased summary of OR risk of 1.33, this was not statistically significant. 
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Table 1. Epidemiological studies of the association between exposure to PCBs and risk of breast cancer. 
Reference, 
Location 
Study Design 
Study 
Population 
Measurement of 
Exposure 
Outcomes Results Comments Confounders 
Charlier et al. 
[24], Belgium 
Case-control 
study 
60 cases,  
60 age matched 
healthy controls 
7 PCBs from serum,  
Total PCBs. 
Mean Total PCB levels 
(ppb = ng/g)  
Cases: 7.08;  
Controls: 5.10;  
Logistic Regression 
(OR, 95% CI). 
Total PCBs significantly different in cases than 
controls (p = 0.012). High concentrations of 
PCB153 significantly associated with an 
increased risk of BC (OR = 1.8, 95% CI: 1.4–2.5). 
Cases diagnosed with 
breast cancer and 
undergoing a surgical 
intervention.  
Controls free of BC at 
age of diagnosis. 
Adjustments made for age, 
menopausal status, number of full-
term pregnancies, lactation, use of 
HRT, and family history of BC. 
Demers et al. 
[26], Canada 
Case-control 
study 
314 cases,  
523 controls; 
matched by age 
and residence 
14 PCB congeners 
measured in plasma  
(μg/kg of plasma lipids). 
TEQ/kg of lipids for sum 
of mono-ortho congeners 
(nos. 105, 118, 156). 
Mean TEQ ng/g of lipids: 
Cases: 6.4;  
Controls: 5.8;  
Logistic Regression 
(OR, 95% CI); 
Quartiles. 
Mean total of mono-ortho congeners 
significantly higher in cases than controls  
(p = 0.005). Significant associations between 
breast cancer risk and PCB 156, 118, & mono 
ortho congeners. In 4th vs. 1st quartiles.  
(OR = 2.02, 95% CI: 1.24–3.28). 
Cases: histologically 
confirmed infiltrating 
primary BC.  
Controls: no history of 
BC diagnosis. 
Adjusted for age, residence, BMI, 
history of benign breast disease, 
breastfeeding duration. 
Pavuk et al. 
[31], USA 
Case-control 
study 
24 cases,  
88 controls 
Total PCBs from serum 
(n = 15); Groups of 
PCBs: (1) estrogenic;  
(2) anti-estrogenic, 
dioxin-like;  
(3) phenobarbital-type. 
GMs Total PCBs (ng/g 
of lipid): Cases: 3228.2; 
Controls: 2885.8. 
Logistic Regression 
(OR, 95% CI); Tertiles. 
Higher serum levels of total PCBs (OR = 0.42, 95% 
CI 0.10–1.82) inversely associated with BC. 
Groups 1, 2, & 3 also inversely associated. 
Cases: histologically 
confirmed invasive BC. 
Controls: identified 
through random 
sampling of primary care 
physicians. 
Adjusted for age, age at  
menarche, education, alcohol 
consumption, smoking. 
Recio-Vega et al. 
[32], Mexico 
Case-control 
study 
70 cases,  
70 controls 
Individual and total PCBs 
from serum (n = 20);  
5 PCB groups by 
structure-activity 
relationships. 
GM Total PCB levels 
(ppb): Cases: 5.26; 
Controls: 3.33.  
Logistic Regression 
(OR, 95% CI). 
Total PCBs significantly higher among cases 
than controls (OR = 1.09, 95% CI 1.01–1.14). 
Risk of BC positively associated with 8 PCB 
congeners: 118, 128, 138, 170, 180, 195, 206, 
and 209. 
Cases: first diagnosis of 
BC by biopsy.  
Controls: negative biopsies 
from same hospitals and 
geographic area. 
Adjusted for age, age at menarche, 
lactation, menopause status, BMI. 
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Table 1. Cont. 
Reference, 
Location 
Study Design 
Study 
Population 
Measurement of 
Exposure 
Outcomes Results Comments Confounders 
Wolff et al. 
[33], USA 
Prospective 
case-control 
study 
148 cases,  
295 individually 
matched controls 
Total PCBs from serum. 
GM Total PCBs (ng/g of 
lipids): Cases: 683; 
Controls: 663.  
Logistic Regression 
(OR, 95% CI); Quartiles. 
GM Total PCB levels not significantly 
different. No association between PCB 
exposure and BC (OR = 2.02;  
95% CI 0.76–5.37). 
BC cases identified 
through active follow-up 
of the NYU Women’s 
Health Study Cohort. 
Controls selected at 
random from cohort who 
were alive and free of 
disease at the time of 
case diagnosis. 
Adjusted for age at menarche, # of 
full-term pregnancies, age at first 
birth, family history of BC,  
lifetime history of lactation,  
BMI, menopausal status at time of 
blood donation. 
Itoh et al. 
[29], Japan  
Matched 
case-control 
study 
403 pairs; 
matched by age 
(3 years) and 
residence 
Total PCBs from serum 
(Sum of 41 PCB peaks).  
Median Total  
lipid-adjusted PCBs 
(ng/g): Cases: 170;  
Controls: 180.  
Logistic Regression 
(OR, 95% CI), Quartiles. 
Total PCBs associated with a decreased risk of 
BC. (OR = 0.33, 95% CI: 0.14–0.78,  
p-value 0.008); highest vs. lowest quartile. 
Cases: histologically 
confirmed invasive BC. 
Controls: selected from 
medical checkup examinees, 
no BC diagnosis. 
Adjusted for lipids, BMI, 
menopausal status & age, smoking, 
fish & veg consumption,  
family history, parity, age at first 
childbirth, age at menarche, history 
of BC screening 
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Figure 2. Forest plot of Epidemiological studies of the association between exposure to 
PCBs and risk of breast cancer. 
2.2.2. Bisphenol A or Phthalate and Breast Cancer 
No meta-analysis was performed on exposure to BPA or phthalates, because only one study for each 
chemical fit the criteria. Lopez-Carillo et al. [30] found urinary concentrations of monoethyl phthalate 
(MEP) to be significantly higher in cases than controls when comparing the highest vs. lowest tertile of 
exposure (169.58 vs. 106.78 μg/g creatinine). The OR of breast cancer risk in the highest tertile of urinary 
MEP, compared with the lowest tertile, was 2.20 (95% CI 1.33–3.63) and became higher when estimated 
for premenopausal women (OR = 4.13, 95% CI 1.60–10.7). On the contrary, significant negative 
associations were found for urinary concentrations of monobenzyl phthalate (MBzP) (OR = 0.46, 95% 
CI 0.27–0.79) and mono (3-carboxypropyl) phthalate (MCPP) (OR = 0.44, 95% CI 0.24–0.80).  
In a matched case-control study, Yang et al. [34] measured median blood BPA levels in 70 cases 
and 80 controls. Median BPA levels were higher in cases than controls (0.61 vs. 0.03 μg/L), however, 
the differences were not found to be statistically significant (p = 0.42). 
2.3. PCBs–Breast Cancer–Gene Association 
The CTD search revealed that besides PCBs, the five most common PCB congeners studied for 
gene interaction were 3,4,3′,4′-tetrachlorobiphenyl (77), 2′,3,3′,4′,5-pentachloro-4-hydroxybiphenyl  
(4′-OH-PCB-86), 3,4,5,3′,4′-pentachlorobiphenyl (126), 2,3,3′,4,4′,5-hexachlorobiphenyl (153), and 
2,2′,3,4,4′,5,5′-heptachlorobiphenyl (180) (Table 2). There were 5289 genes related to PCB family of 
chemicals and 386 genes related to breast cancer (Figure 3). The common genes between PCBs and 
breast cancer were 200. The top interacting genes with PCBs as a chemical class were CYP1A1, AHR, 
CYP1A2, AR, CYP1A, CYP1B1, VCAM1, MAPK1, MAPK3, and PTGS2. The top interacting genes  
with PCBs in breast neoplasms were AR, CYP1A1, CYP1B1, ESR1, ESR2, PTGS2, and RAF1. Out of  
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a total 200 genes interactions observed with individual PCBs, the interaction of genes AR,  
BAX, CYP1A1, CYP1B1, KDR, PARP1, PTGS2, and RAF1 was common with tetrachloride,  
pentachloride, and hexachloride biphenyls in beast neoplasms (Table 2). CYP1A1, AHR, AR, CYP1A, 
CYP1B1 and PTGS2 genes are common in both PCB-gene and PCB-gene-breast cancer groups. 
Interactions among these genes are shown in Figure S1. Enrichment pathway analysis revealed that these 
genes are part of: (1) pathways in cancer (KEGG: 05200); (2) signal transduction (REACT: 111102); 
(3) mTOR signaling pathway (KEGG: 04150); (4) focal adhesion (KEGG: 04510); (5) VEGF signaling 
pathway (KEGG: 04370); and (6) ErbB signaling pathway (Table 3). 
 
Figure 3. A Venn diagram of list of genes common between breast neoplasms and PCBs, 
phthalates or bisphenol A. 
2.4. BPA, Phthalate and Breast Cancer–Gene Association 
There were 6365 genes associated with the chemical BPA. There were 385 genes known to be 
associated with breast cancer. There were 209 genes in common between BPA and breast cancer  
(Figure 2). There were 5754 genes associated with phthalate chemical class and 385 genes associated to 
breast cancer (Figure 2). The common genes shared between dibutyl phthalate and breast cancer; and 
diethylhexyl phthalate and breast cancer were 162 and 89, respectively. Identification of the common 
genes with breast cancer and both dibutyl phthalate and diethylhexyl phthalate further revealed that there 
were 54 common genes between dibutyl phthalate and diethylhexyl phthalate and breast cancer as shown 
in Table 2 Interactions among these genes are shown in Figure 3. Enrichment pathway analysis revealed 
that some of these genes are part of: (1) pathways in cancer (KEGG: 05200); (2) signal transduction 
(REACT: 111102); and (3) MAPK signaling pathway (KEGG: 04150) (Table 3). 
 
Int. J. Mol. Sci. 2015, 16 25295 
 
 
Table 2. Genes interacting with polychlorinated biphenyls in breast neoplasms. 
IUPAC Name (Congener Number) Interacting Genes 
Polychlorinated biphenyls 
65 genes: ACHE | AFP | AGR2 | AHR | AKAP12 | AKT1 | ANGPTL4 | APOBEC3B | AR | ARAF | AREG | AURKA | BCHE | BIRC5 | CDKN1B | CENPF | 
CLDN4 | COMT | CXCL12 | CXCL2 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 | CYP3A4 | DNMT1 | DNMT3A | DNMT3B | ESR1 | ESR2 | 
FOS | GPI | GPNMB | H2AFX | HEY1 | HMOX1 | HP | IFNG | IL6 | JUN | KRAS | MKI67 | MMP3 | NCOA3 | NQO1 | PPARGC1B | PTGS2 | RAD51 | 
RAD51C | RAD54L | RAF1 | RPS8 | SOD2 | SPP1 | STC2 | STMN1 | TGM2 | THBS1 | THEMIS2 | TNF | TOP2A | TYMS | UBE2C 
2,4,4′-Trichlorobiphenyl (28) 11 genes: AR | CYP1A1 | CYP1B1 | CYP2B1 | ESR1 | ESR2 | HIF1A | KDR | PTGS2 | RAF1 | TP53 
2,4′,5-Trichlorobiphenyl (31) 3 genes: AR | ESR1 | ESR2 
2,5,2′,5′-Tetrachlorobiphenyl (55) 13 genes: ACHE | AHR | AKT2 | APC2 | AR | CYP1A1 | CYP2B1 | EPB41L3 | IGF1R | MMP2 | PARP1 | PLA2G4A | ZEB2  
3,4,3′,4′-Tetrachlorobiphenyl (77) 27 genes: AHR | AR | BAX | CAV1 | CCNE1 | CYP1A1 | CYP1B1 | ESR1 | ESR2 | GPI | GPX1 | HADHB | HIF1A | HNRNPK | IL1B | IL6 | KDR | MRPL19 | 
NDRG1 | NOS3 | NQO1 | PARP1 | PER3 | PTGS2 | RAF1 | RELA | TNF 
2′,3,3′,4′,5-Pentachloro-4-hydroxybiphenyl 
(4′-OH-PCB-86;  
4-hydroxy-2,2′,3′,4′,5′-pentachlorobiphenyl) 
75 genes: ACVR1 | AFP | APC2 | ARAF | ATM | BIRC5 | BMPR2 | CASP8 | CAV1 | CD40 | CHEK2 | CSF1 | CSF3 | CST6 | CXCL12 | CXCL2 | CYP17A1 | 
CYP1A1 | DAP3 | DDIT3 | DNMT3A | DNMT3B | DPYD | EEF2 | EFNA1 | EGF | ERBB2 | F3 | FABP7 | FGFR2 | FHL2 | FKBPL | GDF10 | HIF1A | 
HRG | IL24 | JAG1 | JAG2 | JUN | LDHB | LEPR | LPAR1 | MFGE8 | MME | MMP2 | MMP3 | MMP9 | MRPL13 | MTDH | MTHFR | MTR | NDRG1 | 
NOTCH3 | NOTCH4 | NRCAM | NUDT2 | OCLN | PARP1 | PDE2A | PDGFA | PHB | PPARGC1B | PTPRD | RGS2 | SLC28A1 | STAT3 | SYNE1 | SYNJ2 | 
TFRC | THBS1 | THEMIS2 | TOP2A | VEGFC | VPS39 | ZEB1 
2,2′,4,6,6′-Pentachlorobiphenyl (104) 9 genes: AKT1 | AR | CXCL8 | EGFR | FOS | JUN | MMP3 | OCLN | SRC 
2,3,3′,4,4′-Pentachlorobiphenyl (105) 4 genes: AHR | AR | CYP1A1 | CYP2B1 
2,3′,4,4′,5-Pentachlorobiphenyl (107) 10 genes: AHR | AR | CASP7 | CYP1A1 | CYP1B1 | CYP2B1 | HIF1A | KDR | OCLN | PTGS2 
2,3,4,4′,5-Pentachlorobiphenyl (114) 2 genes: AHR | CYP1A1 
2,3′,4,4′,5-Pentachlorobiphenyl (118) 10 genes: AHR | AR | CASP7 | CYP1A1 | CYP1B1 | CYP2B1 | HIF1A | KDR | OCLN | PTGS2 
3,4,5,3′,4′-Pentachlorobiphenyl (126) 
77 genes: ACVR1 | ADAMTS1 | AFP | AHR | AKAP12 | AKT1 | APRT | AR | AREG | BARD1 | BAX | BCL2 | BMP4 | BRCA1 | CADM1 | CAV1 | CCL20 | 
CCND1 | CD74 | CXCL12 | CXCL8 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 | EGF | ESR1 | F3 | FASN | FGFR2 | FHL2 | FST | GPNMB | 
HES1 | HIF1A | HMOX1 | ICAM5 | IGF1 | IGF1R | IGFBP5 | IGFBP7 | IL1B | IL6 | JUN | KDR | LDHAL6B | LPAR1 | MME | MMP9 | NOS2 | NOS3 | 
NOTCH1 | NQO1 | NRG1 | OCLN | PAK1 | PARP1 | PDGFA | PER3 | PHGDH | PLA2G4A | PTGS2 | PTPRD | RAF1 | SERPINB2 | SLC2A5 | SLC5A5 | 
SNAI1 | SPP1 | STC2 | SYNJ2 | TBX3 | TGM2 | TNF | TP53 | VEGFC 
2,3,4,2′,3′,4′-Hexachlorobiphenyl (128) 2 genes: AHR | AR 
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Table 2. Cont. 
IUPAC Name (Congener Number) Interacting Genes 
2,3,3′,4,4′,5-Hexachlorobiphenyl (129) 5 genes: AHR | AR | CYP1A1 | CYP1B1 | ESR1 
2,2′,3′,4,4′,5-Hexachlorobiphenyl (137) 27 genes: ACHE | AHR | AKT2 | APC2 | AR | BRCA1 | CCT5 | CENPF | CFL1 | CYP1A1 | CYP1B1 | CYP2B1 | EEF2 | EGF | ENO1 | FBL | FOS | HIF1A | 
HSP90AA1 | IGF1 | KDR | MMP2 | NOTCH2 | NRG1 | PTGS2 | STARD8 | ZEB2 
2,3,6,2′,3′,6′-Hexachlorobiphenyl (136) 2 genes: AR | CYP2B1 
2,4,5,2′,4′,5′-Hexachlorobiphenyl (153) 
51 genes: AHR | AKAP12 | AR | BAX | BCL2 | BRCA1 | CASP8 | CCND1 | CDH1 | CTNNB1 | CXCL12 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 | 
CYP3A4 | EGFR | ESR1 | ESR2 | FASN | FOS | GPX1 | GPX2 | HIF1A | HSPA1B | IFNG | IGF1 | IL1B | JUN | KDR | MAP3K1 | MEIS1 | NDRG1 | 
NOTCH1 | NQO1 | NRG1 | OCLN | PARP1 | PTGS2 | PTPRD | RAF1 | SPP1 | SRC | STAT5A | STMN1 | TFPI2 | TNF | TNFSF10 | TP53 | TUBB3 | 
XRCC3 
3,4,5,3′,4′,5′-Hexachlorobiphenyl 7 genes: AHR | BAX | CYP1A1 | CYP1B1 | HIF1A | KDR | PTGS2  
2,2′,3,4,4′,5,5′-Heptachlorobiphenyl (180) 19 genes: ABL1 | AHR | AR | BAX | BCL2 | BRCA1 | CYP1A1 | CYP1B1 | CYP2B1 | FOS | HIF1A | IGF1 | KDR | MMP2 | MMP9 | NOTCH1 | PTGS2 | 
TP53 | ZEB2 
17β Estradiol 
255 genes: ABCG2 | ACHE | ADAMTS1 | AFP | AGR2 | AHR | AKAP12 | AKT1 | AKT2 | ALDOA | APOBEC3B | AR | ARAF | AREG | ARHGDIA | ARTN | 
ATM | ATP7B | AURKA | BARD1 | BAX | BCAR3 | BCHE | BCL2 | BIRC5 | BMP2 | BMP4 | BMPR2 | BRCA1 | BRCA2 | C10ORF10 | CADM1 | CASP7 | 
CASP8 | CAV1 | CCL20 | CCND1 | CCNE1 | CD109 | CD40 | CDA | CDH1 | CDH5 | CDKN1B | CENPF | CFL1 | CHEK2 | CLDN1 | CLDN4 | COL7A1 | 
COMT | CSF1 | CSF1R | CSF3 | CST6 | CTNNB1 | CXCL12 | CXCL2 | CXCL3 | CXCL8 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 | CYP3A4 | 
DDIT3 | DKK1 | DNMT1 | DNMT3A | E2F1 | EDNRB | EFEMP1 | EFNA1 | EGF | EGFR | ELK3 | ENO1 | EPHB4 | EPOR | ERBB2 | ESR1 | ESR2 | 
ESRRA | ETS2 | ETV4 | EVL | F3 | FASN | FBL | FGF10 | FGFR1 | FGFR2 | FHL2 | FKBPL | FOS | FOXA1 | FOXM1 | FOXP3 | FST | GDF10 | GPNMB | 
GPX1 | GPX2 | GPX4 | GRB7 | H2AFX | HADHB | HES1 | HEY1 | HEY2 | HIF1A | HIST1H1C | HIST1H2BC | HIST1H2BK | HMMR | HMOX1 | HP | 
HPSE | HRAS | HRG | HSP90AA1 | HSPA1B | IFNG | IGBP1 | IGF1 | IGF1R | IGFBP5 | IL1B | IL24 | IL6 | JAG1 | JUN | KCNH1 | KDR | KIT | KRAS | 
KRT18 | KRT8 | LDHB | LEP | LEPR | LOXL2 | LPAR1 | LSP1 | MAL | MAP3K1 | MDM4 | MIF | MIR10B | MIR146A | MIR200B | MIR222 | MKI67 | 
MME | MMP1 | MMP2 | MMP3 | MMP9 | MTR | NAT2 | NCOA1 | NCOA2 | NCOA3 | NCOR1 | NDRG1 | NFKBIA | NOS2 | NOS3 | NOTCH1 | NOTCH2 | 
NQO1 | NQO2 | NR2F1 | NRG1 | NRIP1 | NUDT2 | PAEP | PAK1 | PARP1 | PDGFA | PGR | PHB | PHGDH | PIK3CA | PIM1 | PLA2G4A | PPARGC1B | 
PPM1D | PTEN | PTGS1 | PTGS2 | PTHLH | RAD51 | RAD51C | RAF1 | RARB | RB1 | RBM3 | RELA | RGS2 | RPL31 | RPS4X | RPS6 | RPS7 | RRAD | 
SERPINB2 | SERPINB5 | SFRP1 | SFRP2 | SLC2A1 | SLC2A2 | SLC2A5 | SLC39A6 | SLC5A5 | SNAI1 | SNAI2 | SOD2 | SPP1 | SRC | STAT3 | STAT5A | 
STC2 | STMN1 | SYNE1 | SYNJ2 | TANK | TBX3 | TCL1B | TERT | TFAP2A | TFPI2 | TFRC | TGM2 | THBS1 | THEMIS2 | TLE3 | TNF | TNFSF10 | TNIP1 
| TOP2A | TOX3 | TP53 | TRERF1 | TRP53 | TUBB3 | TYMS | UBE2C | VPS39 | WNT10B | WT1 | ZEB1 | ZEB2 | ZNF365 | ZNF366 
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Table 2. Cont. 
IUPAC Name (Congener Number) Interacting Genes 
Diethyl phthalate 9 genes: AFP | AHR | AR | CXCL8 | CYP17A1 | CYP1B1 | ESR1 | ESR2 | IFNB1 
Dibutyl phthalate and diethylhexyl phthalate 
54 Common genes: ABCG2 | AHR | AKT1 | ALDOA | AR | BCL2 | BMP2 | BMP4 | CADM1 | CASP7 | CCND1 | CD40 | CTNNB1 | CYP17A1 | CYP19A1 | 
CYP1A1 | CYP1B1 | CYP3A4 | DNMT1 | DNMT3A | DNMT3B | EDNRB | EEF2 | EGFR | ESR1 | ESR2 | ESRRA | F3 | FASN | FOS | GPX1 | HADHB | 
HSP90AA1 | IGF1 | IGFBP7 | JUN | LOXL2 | MMP2 | MMP9 | NDRG1 | NFKBIA | NOTCH2 | OCLN | PER3 | PIK3CA | PTPRD | RPL31 | RPS4X | 
SOD2 | THBS1 | TNF | TUBB3 | WNT10B | YBX1 
Bisphenol A 
209 genes: ABCG2 | ABL1 | ACHE | AFP | AGR2 | AHR | AKAP12 | AKT1| ALDOA | APOBEC3B | AR | ARAF | AREG | ARHGDIA | AURKA | BAG1 
|BARD1 | BAX | BCAR3 | BCL2 | BCL2A1 | BIRC5 | BMP4 | BRCA1 | BRCA2 |CASP7 | CASP8 | CAV1 | CCND1 | CCNE1 | CCT5 | CDH1 | CDH5 | 
CDKN1B |CENPF | CFL1 | CHEK2 | CLDN4 | CMC2 | COTL1 | CSF2 | CTNNB1 | CUL5 |CXCL12 | CXCL3 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | 
CYP2D6 |CYP3A4 | DAP3 | DDIT3 | DNMT1 | DNMT3A | DNMT3B | DSC3 | E2F1 | EEF2 |EGF | EGFR | ENO1 | ERBB2 | ESR1 | ESR2 | ESRRA | ETS2 
| EVL | EZH2 | FASN| FBL | FGFR1 | FGFR2 | FHL2 | FOS | FOXM1 | FST | GDF10 | H2AFX | HADHB |HES1 | HEY2 | HIC1 | HMMR | HMOX1 | 
HNRNPL | HNRNPR | HP | HRAS |HSP90AA1 | HSPA1B | IFNB1 | IFNG | IGBP1 | IGF1 | IGF1R | IGFBP5 | IL1B |IL6 | JAG1 | JAG2 | JUN | KDR | KIT 
| KRAS | KRT8 | LEP | LEPR | LLGL1 |LPAR1 | MAL | MAP3K1 | MDM4 | MEIS1 | MFGE8 | MIF | MIR146A | MIR200B |MIR222 | MIR29A | MIR342 | 
MKI67 | MME | MMP1 | MMP2 | MMP9 | MRPL13 |MRPL19 | MRPS22 | MTR | NAT2 | NCOA1 | NCOA2 | NCOA3 | NCOR1 | NDRG1| NOS2 | NOS3 | 
NOTCH1 | NOTCH2 | NOTCH3 | NQO1 | NRCAM | NRIP1 |NUDT2 | OCLN | PAK1 | PARP1 | PDGFA | PER3 | PGR | PHB | PHGDH | PIM1 |PIN1 | 
PLA2G4A | PTEN | PTGS1 | PTGS2 | RAD51 | RAD51B | RAD51C |RAD54L | RB1 | RELA | RGS2 | RIBC2 | RPS6 | RPS6KB2 | RPS7 | RXRB |SERPINB5 | 
SFRP1 | SFRP2 | SHMT1 | SIRT1 | SLC22A18 | SLC2A1 | SLC2A2 |SLC5A5 | SNAI2 | SOD2 | SPP1 | SRC | STAT3 | STAT5A | STC2 | STMN1 |SYNE1 | 
TANK | TBX3 | TERT | TFAP2A | TFPI2 | TGM2 | THBS1 | TNF | TNFSF10| TNIP1 | TOP2A | TP53 | TYMS | UBE2C | UMPS | WNT10B | WT1 | WWOX 
|XRCC3 | YBX1 
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Table 3. KEGG enrichment pathways for common genes between EDCs, breast cancer and endometriosis. 
Pathways Pathway ID Gene Association Number of Associated Genes
Steroid hormone biosynthesis KEGG:00140 CYP19A1 1 
Metabolic pathways KEGG:01100 CYP19A1 1 
MAPK signaling pathway KEGG:04010 EGFR|FOS|KRAS 3 
ErbB signaling pathway KEGG:04012 AREG|EGFR|KRAS 3 
Chemokine signaling pathway KEGG:04062 KRAS 1 
p53 signaling pathway KEGG:04115 IGF1 1 
mTOR signaling pathway KEGG:04150 IGF1 1 
Dorso-ventral axis formation KEGG:04320 EGFR|KRAS 2 
VEGF signaling pathway KEGG:04370 KRAS 1 
Focal adhesion KEGG:04510 EGFR||IGF1| 2 
Adherens junction KEGG:04520 EGFR 1 
Tight junction KEGG:04530 KRAS 1 
Gap junction KEGG:04540 EGFR|KRAS 2 
Toll-like receptor signaling pathway KEGG:04620 FOS 1 
Natural killer cell mediated cytotoxicity KEGG:04650 KRAS 1 
T cell receptor signaling pathway KEGG:04660 FOS|KRAS 2 
B cell receptor signaling pathway KEGG:04662 FOS|KRAS| 2 
Fc epsilon RI signaling pathway KEGG:04664 KRAS 1 
Regulation of actin cytoskeleton KEGG:04810 EGFR|KRAS 2 
Insulin signaling pathway KEGG:04910 KRAS 1 
GnRH signaling pathway KEGG:04912 EGFR|KRAS 2 
Pathways in cancer KEGG:05200 EGFR|FOS|IGF1|KRAS 4 
Pancreatic cancer KEGG:05212 EGFR|KRAS 2 
Endometrial cancer KEGG:05213 EGFR|KRAS 2 
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2.5. Association between Endometriosis and Exposure to PCB, Phthalates or BPA 
We identified 11 epidemiologic studies related to PCB, phthalate, or BPA exposure and endometriosis. 
Eight of the studies assessed the relationship between PCB exposure and endometriosis [38–44], two 
studies assessed the relationship between phthalate exposure and endometriosis [29,45], one study 
assessed the relationship between BPA exposure and endometriosis [46], and one study assessed the 
relationship between phthalate and BPA exposure and endometriosis [47]. Of these studies, eight were 
case-control studies, one was a cross-sectional study and two were cohort studies. In all of the studies, 
endometriosis cases were confirmed with a laparoscopic examination and/or biopsy and in nine of the 
eleven studies controls were also confirmed to be disease free through laparoscopic examination. 
Controls in the remaining two studies were randomly selected from a list of Group Health Enrollees that 
were known to not have endometriosis. 
All eight of the studies that addressed the relationship between PCB exposure and endometriosis 
presented individual congener results as well as a measure of total PCBs, the sum of individual congeners. 
To summarize the main results between PCB exposure and endometriosis, lipid adjusted arithmetic 
means or geometric means of total PCB exposure were provided for four studies [34,38,41,46], median 
TEQ values (pg TEQ/g lipid) were provided in two studies [40,43], and median wet weight serum 
PCB concentrations were calculated in one study [42]. Furthermore, all studies estimated the risk of 
endometriosis using adjusted logistic regression models with OR and 95% confidence intervals, with the 
majority of the studies using tertiles or quartiles to compare highest versus lowest exposure categories. 
Only three of the eight PCB case-control studies found associations between exposure to total PCBs 
and risk of endometriosis [34,36,41]. Louis et al. [36] measured total PCBs (n = 62), the sum of 
estrogenic PCBs (n = 12), and the sum of anti-estrogenic PCBs (n = 4) in a cohort study of 84 women 
undergoing laparoscopy (32 endometriosis cases, 52 controls). They found a significant increased  
risk of endometriosis for the sum of anti-estrogenic PCBs for women in the third tertile (OR = 3.77,  
95% CI 1.12–12.68), however, the risk remained elevated but not significant when adjusted for all  
listed covariates. In a case-control study of 158 women (80 cases and 78 controls), Porpora et al. [42] 
found the GM of total PCBs to be significantly higher in cases than controls (301.3 vs. 203.0,  
p < 0.01). The OR of endometriosis risk in the highest tertile of total PCBs compared with the lowest 
tertile, was 5.63 (95% CI 2.25–14.10). Significant increased risk of endometriosis was also found for 
PCB congeners 118, 138, 153, and 170. Heiler et al. [38] conducted a case-control study of 50 cases  
(25 with peritoneal endometriosis (PE) and 25 with deep endometriotic (DE) nodules) and 21 controls. 
Multiple dioxin-like PCBs were measured and expressed as toxic equivalent (TEQ) per gram of  
serum lipids. Dioxin-like PCB concentrations were higher in women with DE compared to controls 
{12.4 (10.3 − 14.9) vs. 8.5 (6.9 − 10.5), p = 0.026} but did not significantly differ for women with PE 
compared to controls {11.0 (9.1 − 13.3) vs. 8.5 (6.9 − 10.5)} and for women with DE compared to 
women with PE (12.4 vs. 11.0). 
Four of the PCB case-control studies failed to find significant associations between endometriosis 
and exposure to individual PCB congeners, total PCBs, or specific sub-groups [38,40,42,43].  
Niskar et al. [40] conducted a case-control study with 60 confirmed endometriosis cases staged as  
I (minimal), II (mild), III (moderate), and IV (severe) and 30 controls. Mean lipid-adjusted PCB 
concentrations were not significantly different (179.98 vs. 217.33 vs. 194.76 vs. 193.37) between stage 
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I–II cases, stage III cases, stage IV cases, and controls, respectively. In the largest case-control study 
(Trabert et al. 2010 [43]), total PCBs (n = 20), estrogenic PCBs (n = 6), and individual PCB congeners 
were measured in the serum from 251 cases and 538 controls, matched for age and reference year. 
Adjusted total and estrogenic PCBs in the highest quartiles were not associated with an increased risk of 
endometriosis (Total: OR = 1.2, 95% CI 0.6–2.3, Estrogenic: OR = 0.9, 95% CI 0.5–1.4). In two  
case-control studies measuring median TEQ values (pg TEQ/g lipid) Pauwels et al. [43] found no 
association between endometriosis and the median TEQ values (pg TEQ/g lipid) in cases and controls 
(29 vs. 27) and Tsukino et al. [44] found no difference in median TEQ values for endometriosis cases 
(stage II–IV) and controls (stage 0–I) (cPCBs: 3.40 vs. 3.59, PCBs: 4.61 vs. 5.14), respectively. The OR 
of endometriosis risk in the highest quartile of total PCBs compared with the lowest quartile was 0.41 
(95% CI 0.14–1.27). 
Like breast cancer, results of the association between PCB exposure and endometriosis in eight 
epidemiologic studies were inconsistent or conflicting; therefore, we extracted and summarized  
risk estimates of PCBs on endometriosis from four case control studies using meta-analytic methods. 
Combining four studies of exposure to PCBs produced a summary risk estimate of 1.91 (95% CI:  
1.05–5.54) (Table 4; Figure 4). PCBs exposures were found to be significantly associated with 
development of endometriosis as a meta-analysis of four studies produced an increased risk of 1.91. 
However, there is not much confidence in the combined risk estimate of endometriosis with exposure to 
PCBs because of the lower estimate of CI being barely higher than 1 (1.05). 
 
Figure 4. Forest plot of epidemiological studies of the associations between exposure to 
PCBs and risk of endometriosis. 
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Table 4. Epidemiological Studies of the Association between Exposure to PCBs and Risk of Endometriosis. 
Reference, 
Location 
Study Design Study Population 
Measurement of 
Exposure 
Outcomes Results Comments Confounders 
Heiler et al. 
[38], Belgium 
Case-control 
study 
50 cases:  
(25 with PE,  
25 with DE),  
21 controls 
Multiple PCBs  
from serum,  
12 dioxin-like PCBs 
(pg TEQ/g lipids). 
Mean serum PCB Range  
(pg TEQ/g lipids):  
Controls: 6.9–10.5;  
PE Cases: 9.1–13.3;  
DE Cases: 0.3–14.9;  
Logistic Regression (OR, 95% CI). 
Significant risk with DE 
nodules (OR = 6.7;  
95% CI, 1.4–31.2). 
Controls did not present 
for infertility; normal 
pelvic exam. Cases 
confirmed with 
histological exam  
of lesions. 
Adjusted for age, 
BMI, tobacco 
consumption, age at 
menarche, duration of 
OC use, family history, 
menstrual cycle 
regularity, # of children, 
breast-feeding duration. 
Niskar et al. 
[40], USA 
Case-control 
study 
60 cases,  
30 controls/ 
64 controls 
Serum total PCBs 
(ng/g) (n = 36). 
GM Total PCBs (ng/g lipid):  
Cases stage I–II (179.98),  
stage III (217.33),  
stage IV (194.76),  
Controls (193.37).  
Logistic Regression (OR, 95% CI). 
No significant differences 
in GMs  
(p = 0.97).  
No significant associations 
(OR = 1.00,  
95% CI 0.99–1.01). 
Cases confirmed with 
laparoscopic 
examination and/or 
biopsy. 30 controls 
confirmed with 
laparoscopy, 27 with 
infertile partner and 
7 with ovulation 
problems. 
Adjusted for age, 
gravidity, education, 
income. 
Pauwels et al. 
[41], Belgium 
Prospective 
case-control 
study 
42 cases,  
27 controls 
Multiple PCBs  
from serum;  
Total PCBs, TEQ 
(pg TEQ/g lipid). 
Median TEQ (pg TEQ/g lipid): 
Cases (29), Controls (27).  
Logistic Regression (OR, 95% CI). 
No significant associations 
found (OR = 4.33,  
95% CI 0.49–38.19). 
Cases and controls 
infertile. Endometriosis 
confirmed with 
laparoscopic 
examination. 
Age, BMI, alcohol 
consumption. 
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Table 4. Cont. 
Reference, 
Location 
Study Design Study Population 
Measurement of 
Exposure 
Outcomes Results Comments Confounders 
Porpora et al. 
[42], Italy 
Case-control 
study 
80 cases,  
78 controls  
Multiple PCBs from 
serum, Total PCBs. 
GM of Total PCBs (ng/g of fat): 
Cases: 301.3; Controls: 203.0;  
Logistic Regression (OR, 95% CI). 
Total PCB concentrations 
significantly higher in 
cases (OR = 5.63, 95% CI 
2.25–14.10); Significant 
increased risk for PCBs 
118, 138, 153, and 170 for 
2nd and 3rd tertiles when 
compared to the lowest tertile. 
Cases and controls 
confirmed with 
laparoscopic 
examination. 
Adjusted for age, 
BMI, smoking habits, 
weight modification. 
Trabert et al. 
[43], USA 
Case-control 
study 
251 cases,  
538 controls; 
matched for age  
(5 year) and 
reference year 
Multiple PCB 
congeners in serum 
(n = 20); Total PCBs, 
Estrogenic PCBs. 
Logistic Regression  
(OR, 95% CI); Quartiles. 
No significant  
associations found. 
Cases: Group Health 
(GH) enrollees with 
endometriosis 
diagnosis,  
Controls: randomly 
selected from list of 
GH enrollees. 
Adjusted for matching 
factors, serum lipids, 
income, alcohol 
consumption,  
DDE exposure. 
Tsukino et al. 
[44], Japan 
Case-control 
study 
139 women: 
Controls:  
Stage 0 & I, Cases: 
Stage II–IV;  
Stage 0 = 59  
Stage I = 22  
Stage II = 10  
Stage III = 23  
Stage IV = 25 
Multiple PCBs in 
serum; Total TEQ 
values of cPCBs 
and PCBs. 
Median TEQ values (pg TEQ/g lipid); 
Logistic Regression  
(OR, 95% CI); Quartiles. 
No significant associations 
found (OR = 1.2,  
95% CI 0.6–2.3). 
Cases and controls 
confirmed with 
laparoscopic 
examination. 
Adjusted for 
menstrual regularity 
and average cycle days. 
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Table 5 lists epidemiological studies of the association between EDCs-phthalate or BPA and 
endometriosis. No meta-analysis was performed on exposure to BPA or phthalates and endometriosis, 
because only two studies that met our criteria of selection examined the association between 
endometriosis and phthalates [39,44]; one study addressed the association between endometriosis 
and BPA [45], and one study addressed the association between both BPA and phthalates and 
endometriosis [29]. Besides these two studies, there are several other epidemiological studies that have 
examined the association between phthalate or BPA exposure and endometriosis [10,29,37,39,46,48–50], 
Table 5. Kim et al. [39] measured plasma levels of mono (2-ethylhexyl) phthalate (MEHP) and  
di-(2-ethylhexyl) phthalate (DEHP) in 97 women with advanced-stage endometriosis and 169 control 
women. Mean plasma levels of MEHP and DEHP were found to be significantly higher in cases than 
controls (MEHP: 17.4 vs. 12.4, p < 0.001, DEHP: 179.7 vs. 92.5, p = 0.010). In a population-based  
case-control study conducted by Upson et al. [45] 8 urinary phthalate metabolites were measured in  
92 surgically-confirmed endometriosis cases and 195 controls. A significant inverse association was 
found between urinary MEHP and risk of endometriosis (OR = 0.3, 95% CI 0.1–0.7). The ENDO study 
was designed to assess the relationship between exposure to environmental chemicals and endometriosis. 
Louis et al. [46] analyzed 14 phthalate metabolites and total BPA in urine from 495 women who 
underwent laparoscopy (operative cohort) and 131 women (population cohort) who underwent pelvic 
magnetic resonance imaging (MRI) for the assessment of endometriosis. In the operative cohort, GMs 
of phthalate metabolites were not found to be significantly higher in women with endometriosis, 
whereas, in the population cohort, GMs of six phthalate metabolites were found to be significantly higher 
for women with endometriosis and a two-fold or higher increase in ORs was observed for mono-n-butyl 
phthalate (mBP), mono-(2-ethyl-5-carboxyphentyl) phthalate (mECPP), mono-[(2-carboxymethyl) hexyl] 
phthalate (mCMHP), mono (2-ethyl-5-hydroxyhexyl) phthalate (mEHHP), mono (2-ethyl-5-oxohexyl) 
phthalate (mEOHP), and mono (2-ethylhexyl) phthalate (mEHP). No significant associations were found 
for urinary BPA concentrations in either the operative cohort or the population cohort. In a hospital 
based cross-sectional study, conducted by Itoh et al. [51], urinary BPA concentrations were analyzed in 
140 women who underwent laparoscopy. The severity of endometriosis was classified into five stages:  
0 (n = 60), I (n = 21), II (n = 10), III (n = 24), and IV (n = 25). Median creatinine adjusted urinary BPA 
concentrations did not significantly differ by endometriosis stage (0.74 vs. 0.93, p = 0.24) for stages  
0–I and stages II–IV, respectively. 
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Table 5. Epidemiological studies of the association between EDCs-Phthalate or BPA and endometriosis. 
EDCs Biological Samples Study Population Outcomes References 
Bisphenol A Serum 69 fertile women undergoing laparoscopy, Naples, Italy Detected in cases Cobellis et al. [47 
Bisphenol B Serum 69 fertile women undergoing laparoscopy, Naples, Italy Detected in cases Cobellis et al. [47] 
Phthalate esters 
Plasma 220 South Indian women undergoing laparoscopy Increased risk Reddy et al. [37] 
Serum 108 South Indian women undergoing laparoscopy Increased risk Reddy et al. [50] 
Diethylphthalate Blood/perit 59 fertile women undergoing laparoscopy Higher in cases Cobellis et al. [47] 
Monoethylphthalate Blood/peri-toneal fluid 59 fertile women undergoing laparoscopy No association Cobellis et al. [47] 
Monobutylphthalate 
Urine 1227 women from the NHANES study, United States No association Calafat et al. [10] 
Urine 109 women undergoing laparotomy, Taiwan Increased in cases Huang et al. [48] 
Monobutylphthalate 
Urine 1227 women from the NHANES study, USA No association Calafat et al. [10] 
Urine 109 women undergoing laparotomy, Taiwan Increased in cases Huang et al. [48] 
Table 6. Genes interacting with polychlorinated biphenyls in endometriosis. 
IUPAC Name (Congener Number) Interacting Genes 
Polychlorinated Biphenyls 
19 genes: AKR1C3 | ANKRD1 | AREG | ARNT | CYP19A1 | DUSP1 | ESR2 | FBN1 | FOS | GREB1 | IGFBP1 | KRAS | 
NR2C2 | NR3C1 | PAPPA | PTGER4 | STC2 | TGFB2 | THRA 
2,4,4ʹ-Trichlorobiphenyl (28) 2 genes: ESR2 | NR3C1 
3,4,3ʹ,4ʹ-Tetrachlorobiphenyl (77) 11 genes: ARNT | DDX5 | ESR2 | FKBP5 | ITGB8 | KLF13 | MAOB | NR1D2 | PRLR | SULF2 | TXNIP 
2ʹ,3,3ʹ,4ʹ,5-Pentachloro-4-hydroxybiphenyl 
(4ʹ-OH-PCB-86;  
4-hydroxy-2,2ʹ,3ʹ,4ʹ,5ʹ-pentachlorobiphenyl ) 
25 genes: ABCC9 | BRD8 | CD55 | CNR1 | ELAVL1 | ERRFI1 | FKBP5 | IFNGR1 | IGFBP1 | MED1 | MED4 | MTA1 | 
NCOA6 | NR2C1 | NR3C1 | NR3C2 | NR4A1 | NRP1 | PRLR | SLC16A6 | SPARCL1 | SST | TAGLN | THRA | TNC 
2,2ʹ,4,6,6ʹ-Pentachlorobiphenyl (104) 2 genes: EGFR | FOS 
3,4,5,3ʹ,4ʹ-Pentachlorobiphenyl (126) 
36 genes: AREG | CD55 | CXCL14 | CYP19A1 | DUSP1 | ENPP1 | FBN1 | GPX3 | HBEGF | HSD17B1 | HSD17B2 | 
IGF1 | IGFBP1 | IGFBP6 | IL1R1 | IMPA2 | MAOA | MAOB | MED1 | NEDD4L | NR3C1 | OSR2 | PRLR | RASL11A | 
SEPP1 | SLC20A1 | SLC40A1 | SLC7A8 | SPARCL1 | SRD5A1 | SRD5A2 | SST | STC2 | TAGLN | TGFB2 | TXNIP 
2,2ʹ,3ʹ,4,4ʹ,5-Hexachlorobiphenyl (137) 10 genes: FBLN1 | FOS | HBEGF | IGF1 | NEFM | PRL | SLC16A6 | SRD5A1 | SRD5A2 | SST 
2,3,6,2ʹ,3ʹ,6ʹ-Hexachlorobiphenyl (136) 2 genes: AR | CYP2B1 
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Table 6. Cont. 
IUPAC Name (Congener Number) Interacting Genes 
2,4,5,2ʹ,4ʹ,5ʹ-Hexachlorobiphenyl (153) 18 genes: CYP19A1 | DCSTAMP | EGFR | ESR2 | FOS | HSD17B1 | HSD17B2 | IFIT1 | IGF1 | ITGB8 | MAOB | NR3C1 | SEPP1 | SLC16A6 | SRD5A1 | SRD5A2 | SST | TXNIP 
17β Estradiol 
114 genes: ABCC9 | ABI3BP | ACTA2 | AKR1C1 | AKR1C2 | AKR1C3 | ANKH | ANKRD1 | AREG | ARHGAP28 | 
ARNT | BMP7 | C10ORF10 | C1R | CCNE2 | CD55 | CFD | CLDN1 | CNIH3 | CNR1 | CPM | CXCL14 | CYB5A | 
CYP19A1 | CYP26A1 | DDX5 | DICER1 | DIO2 | DKK1 | DUSP1 | EGFR | ELAVL1 | ERRFI1 | ESR2 | FBLN1 | FBN1 
| FKBP5 | FOS | GPX3 | GREB1 | HDAC1 | HDAC2 | HERC5 | HS3ST3B1 | HSD17B1 | HSD17B2 | IDO1 | IFIT1 | 
IGF1 | IGFBP1 | IGFBP6 | IHH | IL15 | IL1R1 | IL7R | ITGA2 | ITGB1 | ITGB8 | KLF13 | KLF9 | KRAS | LMOD1 | 
LTF | MAOA | MAOB | MED1 | MED14 | METTL7A | MIR21 | MYLIP | NCOA1 | NCOA6 | NCOR1 | NEDD4L | 
NR2F2 | NR3C1 | NR3C2 | NR4A1 | NR5A1 | NRP1 | NTRK3 | OLFM4 | OSR2 | PAPPA | PGR | PRL | PRLR | 
PTGER2 | PTGER4 | RARB | RASGRP1 | RGS4 | RORB | RXFP1 | SEPP1 | SLC16A6 | SLC1A1 | SLC20A1 | SLC40A1 
| SLC7A8 | SMPDL3A | SPARCL1 | SRD5A2 | STC2 | SULF2 | TACSTD2 | TAGLN | TGFB2 | THRA | TNC | TOB1 | 
TRH | TXNIP | VCAN ZEB2 
Dibutyl phthalate 
71 genes: ABI3BP | ACTA2 | AKR1C1 | ANKRD1 | AREG | ARNT | BMP7 | BRD8 | C1R | CCNE2 | CD55 | CLDN1| 
CNR1 | COPS2 | CYB5A | CYP19A1 | CYP26A1 | DDX5 | DICER1 | DUSP1 | EGFR | ELAVL1 | ENPP1 | ERRFI1 | 
ESR2 |FKBP5 | FOS | GPX3 | HDAC1 | HSD17B1 | IGF1 | IL1R1 | ITGB1 | ITGB8 | KLF9 | LMOD1 | MAOA | MAOB 
| MED1 |MED14 | MED17 | NR1D2 | NR2F2 | NR2F6 | NR3C1 | NR4A1 | NR5A1 | NRP1 | OSR2 | PAPPA | PGR | 
PRLR | PTGER2 |PTGER4 | RASL11A | SEPP1 | SLC16A6 | SLC20A1 | SLC40A1 | SLC7A8 | SMPDL3A | SRD5A1 | 
STC2 | SUCLG2 |SULF2 | TAGLN | TGFB2 | THRA | TOB1 | TXNIP | VCAN. 
Diethylhexyl phthalate 
29 genes: CNR1 | CYP19A1 | CYP26A1 | EGFR | ESR2 | FKBP5 | FOS | HERC5 | IGF1 | IGFBP1 | ITGB1 | MAOA | 
NCOA1 | NR3C1 | NR4A1 | NR5A1 | PAX2 | PRL | PRLR | PTGER2 | PTGER4 | SRD5A1 | TGFB2 | DUSP1 | FMO2 | 
GPX3 | MED1 | NCOR1 | TXNIP 
Dibutyl phthalate and diethyl-hexyl phthalate 22 genes: CNR1 | CYP19A1 | CYP26A1 | DUSP1 | EGFR | ESR2 | FKBP5 | FOS | GPX3 | IGF1 | ITGB1 | MAOA | MED1 | NR3C1 | NR4A1 | NR5A1 | PRLR | PTGER2 | PTGER4 | SRD5A1 | TGFB2 | TXNIP 
Bisphenol A 
80 genes: ABCC9 | ACTA2 | AREG | ARHGAP28 | ARNT | BMP7 | BRD8 | CCNE2 | COPS2 | CYB5A | CYP19A1 | 
CYP26A1 | DDX5 | DICER1 | DIO2 | DUSP1 | EGFR | ELAVL1 | ENPP1 | ERRFI1 | ESR2 | FKBP5 | FOS | GPX3 | 
GREB1 | HDAC1 | HDAC2 | HSD17B1 | HSD17B2 | IFNGR1 | IGF1 | IGFBP1 | IGFBP6 | ITGB8 | KLF9 | KRAS | 
LMOD1 | LTF | MAOA | MED1 | MED14 | MED16 | MED17 | MED4 | MIR21 | NCOA1 | NCOR1 | NR2C1 | NR2F2 | 
NR3C1 | NR3C2 | NR4A1 | NR5A1 | NRP1 | OLFM4 | PAPPA | PGR | PRL | PRLR | PTGER2 | PTGER4 | RASGRP1 | 
RASL11A | RGS4 | RORB | SLC1A1 | SLC40A1 | SLC7A8 | SMPDL3A | SRD5A1 | SRD5A2 | SST | STC2 | SULF2 | 
TACSTD2 | TAGLN | TGFB2 | THRA | TNC | VCAN 
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Several hundred genes were altered by exposure to PCBs, phthalate or BPA (Figure 5). The genes 
related to PCB and PCB congeners-3,4,3′,4′-tetrachlorobiphenyl (77), 3,4,5,3′,4′-pentachlorobiphenyl  
(126), and 2,4,5,2′,4′,5′-hexachlorobiphenyl (153) in endometriosis were 19, 11, 36 and 18, respectively 
(Table 6). All these PCBs or their congener-related endometriosis genes were also associated with  
17β-estradiol. The top interacting genes with PCBs and endometriosis were ESR2, NR3C1, CYP19A1, 
EGFR, FKBP5, ITGB8, MAOB, PGR, PRLR, SLC16A6, SST, and TXNIP. There were 80 common genes 
found between BPA and endometriosis (Figure 5). The two phthalates with the most gene interactions 
were: dibutyl phthalate and diethylhexyl phthalate. The genes related to dibutyl phthalate and 
diethylhexyl phthalate were 4692 and 1646, respectively. There were 71 common genes associated 
between dibutyl phthalate and endometriosis and 29 common genes between diethylhexyl phthalate and 
endometriosis (Figure 5). There were 22 genes in common between both phthalates-dibutyl phthalate 
and diethylhexyl phthalate, and endometriosis, as shown in Table 6. Interactions among these genes are 
shown in Figure S2. Enrichment pathway analysis revealed that some of these genes are part of:  
(1) pathways in cancer (KEGG:05200); (2) signal transduction (REACT:111102); and (3) MAPK 
signaling pathway ( KEGG:04150) (Table 3). 
 
Figure 5. A Venn diagram of list of genes common between endometriosis and PCBs, 
phthalates or bisphenol A. 
2.6. Integration of Genes Overlapped among EDCs, Breast Cancer and Endometriosis 
Integration of genes associated with exposure to PCBs, and breast cancer and endometriosis based 
enriched disease analysis showed that there were 16 endometriosis genes overlapped with breast 
neoplasms—AREG, C10ORF10, CLDN1, CYP19A1, DKK1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, 
NCOR1, NR2F6, PGR, RARB, and STC2 (Tables 2 and 6). All of these genes were also associated with 
estrogen in breast neoplasms. Out of these 16 genes, there were 14 genes—AREG, CLDN, CYP19A1, 
DKK1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR, RARB, and STC2—common 
among 17β-estradiol, breast cancer, and endometriosis (Tables 2, 6 and 7). Total PCBs associated with 
AREG, CYP19A1, ESR2, FOS, KRAS and STC2 genes; PCB 126 associated with AREG, CYP19A1, and 
STC2 genes and PCB 15 associated with CYP19A1, EGFR, ESR2, FOS, and IGF1 genes overlapped 
with 17β-estradiol, breast cancer, and endometriosis (Tables 2, 6 and 7). Similarly, we identified dibutyl 
phthalate and diethyl-hexyl phthalate associated overlapping genes with 17β-estradiol, breast cancer, 
and endometriosis: AREG, CLDN1, CYP19A1, EGFR, ESR2, FOS, IGF1, NR2F6, PGR and STC2; and 
CYP19A1, EGFR, ESR2, FOS, IGF1, and NCOA1. There were five common overlapped genes between 
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these two phthalates, 17β-estradiol, breast cancer and endometriosis: CYP19A1, EGFR, ESR2, FOS,  
and IGF1. We also identified another 11 EDC–BPA associated genes that were common among  
17β-estradiol, breast cancer and endometriosis: AREG, CYP19A1, EGFR, ESR2, FOS, IGF1, KRAS, 
NCOA1, NCOR1, PGR, and STC2. Five genes—CYP19A1, EGFR, ESR2, FOS, and IGF1—were 
common among all three EDCs–PCBs, phthalates and BPA, 17β-estradiol, breast cancer, and 
endometriosis. For the gene ontology terms associated with each gene, please see Table 8. 
Since both of these diseases are dependent on unopposed estrogen for their growth, we examined 
whether estrogen receptor signaling pathway genes are common among estrogen, EDCs,  
breast cancer and endometriosis. PCBs and congeners 3,4,5,3′,4′-pentachlorobiphenyl (126) and 
2,4,5,2′,4′,5′-hexachlorobiphenyl (153) were associated with some of the same estrogen receptor 
signaling pathway genes—AR, ESR1, ESR2, NCOA3, and PPARGC1B; AR, BRCA1, ESR1, IGF1, and 
PAK1; and AR, BRCA1, CTNNB1, ESR1, ESR2, IGF1, and SRC, respectively (Table 7). The following 
were also observed with 17β-estradiol—AR, BRCA1, CCNE1, CTNNB1, ESR1, ESR2, FHL2, FOXA1, 
IGF1, NCOA1, NCOA2, NCOA3, NRIP1, PAK1, PGR, PHB, PPARGC1B, RB1, SFRP1, SRC, and 
ZNF366. Similarly, common genes of estrogen receptor signaling pathways were also observed with 
another three EDCs. Dibutyl phthalate associated genes, AR, BRCA1, CCNE1, CTNNB1, ESR1, ESR2, 
FHL2, HEYL, IGF1, PGR, RB1, and SRC; and diethylhexyl phthalate associated genes, AR, CTNNB1, 
ESR1, ESR2, IGF1, NCOA1, and PPARGC1B, and BPA associated AR, BRCA1, CCNE1, CTNNB1, 
ESR1, ESR2, FHL2, IGF1, NCOA1, NCOA2, NCOA3, NRIP1, PAK1, PGR, PHB, RB1, SFRP1, SIRT1, 
and SRC, are also associated with 17β-estradiol in breast neoplasms (Table 7). 
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Table 7. EDCs observed in breast neoplasms that are associated with estrogen responsive gene interactions, endometriosis, and inflammation. 
EDC Interacting with Genes in 
Breast Neoplasms 
Steroid Hormone Receptor Signaling Pathway Endometriosis Inflammation 
17β Estradiol 
AR, BRCA1, CCNE1, CTNNB1, ESR1, ESR2, 
FHL2, FOXA1, IGF1, NCOA1, NCOA2, NCOA3, 
NRIP1, PAK1, PGR, PHB, PPARGC1B, RB1, 
SFRP1, SRC, ZNF366 
AREG, CLDN1, CYP19A1, DKK1, 
EGFR, ESR2, FOS, IGF1, KRAS, 
NCOA1, NCOR1, PGR, RARB, STC2 
AHR, CSF3, CXCL2, CXCL8, HMOX1, 
IFNG, IL1B, IL6, LEP, MIF, MMP9, NOS2, 
NOS3, PARP1, PTGS2, SOD2, TFRC, TNF 
PCBs AR, ESR1, ESR2, NCOA3, PPARGC1B 
AREG, CYP19A1, SR2, FOS,  
KRAS, STC2 
AHR, CXCL2, HMOX1, IFNG, IL6, PTGS2, 
SOD2, TNF 
3,4,5,3′,4′-Pentachlorobiphenyl (126) AR, BRCA1, ESR1, IGF1, PAK1 AREG, CYP19A1, STC2 AHR, CXCL8, HMOX1, IL1B, IL6, MMP9, 
NOS2, NOS3, PARP1, PTGS2, TNF 
2,4,5,2′,4′,5′-Hexachlorobiphenyl (153) AR, BRCA1, CTNNB1, ESR1, ESR2, IGF1, SRC CYP19A1, EGF, ESR2, FOS, IGF1 AHR, IFNG, IL1B, PARP1, PTGS2, TNF 
Dibutyl Phthalate 
AR, BRCA1, CCNE1, CTNNB1, ESR1, ESR2, 
FHL2, HEYL, IGF1, PGR, RB1, SRC 
AREG, CLDN1, CYP19A1, EGFR, 
ESR2, FOS, IGF1, R2F6, PGR, STC2 
AHR, CXCL8, HMOX1, IL1B, IL6, MIF, 
MMP9, PARP1, SOD2, TFRC, TNF 
Diethylhexyl Phthalate 
AR, CTNNB1, ESR1, ESR2, IGF1,  
NCOA1, PPARGC1B 
CYP19A1, EGFR, ESR2, FOS,  
IGF1, NCOA1 
AHR, CSF2, CXCL8, IFNG, LEP, MMP9, 
SOD2, TNF 
Bisphenol A 
AR, BRCA1, CCNE1, CTNNB1, ESR1, ESR2, 
FHL2, IGF1, NCOA1, NCOA2, NCOA3, NRIP1, 
PAK1, PGR, PHB, RB1, SFRP1, SIRT1, SRC 
AREG, CYP19A1, EGFR, ESR2, 
FOS, IGF1, KRAS, NCOA1, NCOR1, 
PGR, STC2 
AHR, CSF2, HMOX1, IFNG, IL1B, IL6, LEP, 
MIF, MMP9, NOS2, NOS3, PARP1, PTGS2, 
SOD2, TNF 
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Table 8. Integration of changes in the expression of genes showing common genes modified in EDCs, breast cancer and endometriosis. The 
underlined gene names show a total of five genes that were common among all three EDCs (PCBs, phthalate and bisphenol A), breast cancer, 
and endometriosis. Environmentally responsive genes are indicated in database column. 
Gene Name Gene ID Location Database * Gene Function 
AREG 374 4q13–q21 E Amphiregulin  
CYP19A1 1588 15q21.1 E Cytochrome P450, family 19, subfamily A, polypeptide 1
EGFR 1956 7p12 E Epidermal growth factor receptor 
ESR2 3468 14q23.2 H Estrogen receptor 2 (ER β) 
FOS 2353 14q24.3 E v-Fos FBJ murine osteosarcoma viral oncogene homolog 
IGF1 3479 12q22-q23 E Insulin-like growth factor 1 (somatomedin C) 
KRAS 6407 12p12.1 H Kirsten rat sarcoma viral oncogene homolog 
NCOA1 7668 2p23 H Nuclear receptor coactivator 1 
NCOR1 7672 17p11.2 H Nuclear receptor corepressor 1 
PGR 5241 11q22-q23 E Progesterone receptor 
STC2 11374 5q35.1 H Stanniocalcin 2 
* (E): Environmental responsive gene based on Environmental Genome Project; (H): HGNC database. 
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Another factor that appears to be common in both diseases is inflammation. Therefore, we also 
examined whether inflammation associated genes are common among estrogen, EDCs, and breast 
cancer. PCBs and congeners 3,4,5,3′,4′-pentachlorobiphenyl (126) and 2,4,5,2′,4′,5′-hexachlorobiphenyl 
(153) were associated with the following inflammation related genes—AHR, CXCL2, HMOX1, IFNG, 
IL6, PTGS2, SOD2, and TNF; AHR, CXCL8, HMOX1, IL1B, IL6, MMP9, NOS2, NOS3, PARP1, PTGS2, 
and TNF; and AHR, IFNG, IL1B, PARP1, PTGS2, and TNF, respectively (Table 7). Dibutyl phthalate, 
diethyl-hexyl phthalate and BPA-associated set of inflammation-related genes were AHR, CXCL8, 
HMOX1, IL1B, IL6, MIF, MMP9, PARP1, SOD2, TFRC, and TNF; AHR, CSF2, CXCL8, IFNG, LEP, 
MMP9, SOD2, and TNF; and AHR, CSF2, HMOX1, IFNG, IL1B, IL6, LEP, MIF, MMP9, NOS2,  
NOS3, PARP1, PTGS2, SOD2, and TNF, respectively. All of these genes were also associated with  
17β-estradiol in breast neoplasms. In summary, EDC associated set of genes from inflammation 
pathways in breast neoplasms are estrogen responsive. 
2.7. Literature Based Validation of Genes Showing Links between Endometriosis and Breast Cancer 
The set of estrogen responsive genes from EDCs, environmental, inflammation, and toxicogenomics 
showing a link between endometriosis and breast cancer is shown in Table 7. Research supporting the 
potential involvement and importance of all EDC responsive common genes in breast cancer and 
endometriotic lesions was found in the literature and human genome databases. The search of the 
environmental genome project databases showed that six genes out of 12 PCBs associated genes—AREG, 
CYP19A1, EGFR, FOS, IGF1, and PGR were environmentally responsive genes (Table 8). These common 
genes were then compared to a curated list of genes in PCB exposed human cell lines. PCB congeners 77 
and 153 increased the expression of the following estrogen responsive genes AREG, CYP19A1, EGFR, 
ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR, STC2 [52]. The expression of estrogen 
responsive genes common to breast cancer: AREG, CYP19A1, EGFR, ESR2, FOS, IGF1, KRAS, 
NCOA1, NCOR1, NR2F6, PGR, STC2 genes was upregulated in human endometriosis lesions [53–55]. 
We also analyzed the interaction among AREG, CYP19A1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, 
NCOR1, NR2F6, PGR, and STC2 genes using enrichment pathway analysis (Figure 6). In order to 
investigate connections between PCBs responsive gene lists in breast cancer and endometriosis, we 
performed Bayesian network analysis. The Bayesian network analysis on the Cancer Genome Atlas 
(TCGA) Research Network data available through cbioportal.org identified the maximum likelihood 
structure of PCBs associated genes in breast neoplasms (Figure 7). 
Figure 7 shows plausible interactions among genes. Parents of a variable in Bayesian networks are 
defined as variables that arcs are originated to that variable. For example, in Figure 7, parents of the gene 
BCHE are PTGS2 and HMOX1. Ancestors of a variable are all the parents of the variable, all parents of 
parents, and so on. Arcs in Figure 7 indicate correlations and they indicate Markov conditions. In Figure 7, 
from the arcs, the relationship between PTGS2 and BCHE was the strongest among all pairwise 
relationships, but also they formed a special Y structure [56] that indicates plausible causality, i.e., 
PTGS2 regulating BCHE. Similarly we have analyzed mRNA expression endometriosis data (Figure 7). 
These genes were more sparsely connected. 
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Figure 6. Interaction of common genes between estrogen, PCBs and breast  
neoplasms—AREG, CYP19A1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, 
PGR, and STC2. 
 
 
Figure 7. Identification of the maximum likelihood structure of PCBs associated genes in 
breast neoplasm using the Bayesian network analysis on the Cancer Genome Atlas (TCGA) 
Research Network data. 
Some of the common estrogen responsive interacting genes are part of steroid hormone biosynthesis; 
metabolic pathways; MAPK signaling pathway; ErbB signaling pathway; chemokine signaling pathway; 
p53 signaling pathway; mTOR signaling pathway; VEGF signaling pathway; focal adhesion; adherens 
junction; tight junction; gap junction; toll-like receptor signaling pathway; natural killer cell mediated 
cytotoxicity; T cell receptor signaling pathway; B cell receptor signaling pathway; Fc epsilon RI 
signaling pathway; regulation of actin cytoskeleton; insulin signaling pathway; GnRH signaling 
pathway; and pathways in cancer (Table 3). We also compared these common genes to a curated list  
of genes in breast cancer, endometriosis as well as EDC exposed populations. The search of the 
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environmental databases showed that some of these common genes were environmentally responsive. 
All these EDC associated set of genes are estrogen responsive (Table 8). All these PCB, Phthalate  
and BPA associated common genes are altered in human breast tumor, uterine tumor tissues and 
endometriosis lesions (Table 8). 
3. Discussion 
In the present study, we focused on developing an integrative approach to elucidate the role of  
EDCs (PCBs, phthalates and BPA) that contributed to the risk of breast cancer and endometriosis using 
environmental epidemiologic evidence and molecular signatures. Women with endometriosis have been 
implicated to develop certain types of cancer, including breast and ovarian cancer [57]. Although several 
molecular and environmental risk factors are common to endometriosis and breast cancer, the results of 
epidemiologic studies have been inconsistent on directly linking endometriosis with breast cancer.  
Both of these diseases are dependent on unopposed estrogen for their growth. Endometrial tissue  
shows elevated activity of aromatase, and this enzyme is a key for the biosynthesis of estrogens [58]. 
Our meta-analysis showed that exposure to estrogen mimicking EDCs-PCBs increased summary risk  
of both breast cancer and endometriosis. Using our bioinformatics method, we further evaluated the 
relationship between endometriosis and breast cancer, and EDCs. Our bioinformatics approach was able 
to identify genes with the potential to be involved in interaction with PCBs and other EDCs–phthalates 
and BPA that may be important to the development of breast cancer and endometriosis. We identified 
six PCBs associated genes—AREG, CYP19A1, EGFR, FOS, IGF1, and PGR—that are environmentally 
responsive. Similarly, we also observed dibutyl phthalate and diethyl-hexyl phthalate associated with 
five common genes—CYP19A1, EGFR, ESR2, FOS, and IGF1—in breast cancer and endometriosis; 
and BPA associated 11 genes—AREG, CYP19A1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, 
PGR, and STC2—that were common in both breast cancer and endometriosis. Five genes—CYP19A1, 
EGFR, ESR2, FOS, and IGF1—were common among all three EDCs–PCB 153, phthalates and BPA, 
breast cancer, and endometriosis. All five common genes are modified in human breast tumor, uterine 
tumor tissues, and endometriosis lesions. All of these genes are estrogen responsive. These findings 
suggest that the increased risk associated with endometriosis may be due to common environmental and 
molecular risk factors between endometriosis and breast cancer. 
Experimental animal and human studies have indicated that EDCs have the ability to cause endocrine 
toxicity. For example, exposure to PCBs has been reported to show a significant delay in puberty in 
boys. De-feminization, early secondary breast development, or menarche have been reported in girls 
exposed to phthalates [4–7,59]. Despite existing debates over the form and amount of BPA to which 
developing and adult humans are exposed, there is considerable data indicating that exposure of humans 
to BPA is associated with increased risk for breast cancer and reproductive dysfunctions [3,4]. 
Postmenopausal women with high serum levels of BPA and mono-ethyl phthalate have been reported to 
elevate breast density, one of the risk factors for breast cancer [36]. These findings are consistent with 
parallel research in experimental models [19–22]. For example, fetal bisphenol A exposure induces the 
development of preneoplastic and neoplastic lesions in the mammary gland in rats [22]. Fetal exposure 
of BPA significantly increases susceptibility to DMBA to produce mammary tumors in mice [21]. BPA 
has also been reported to promote tumor growth of human breast cancer cells-MCF-7 in ovariectomized 
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NCR nu/nu female mice. Women with the lack of detoxifying enzymes are at higher risk for breast 
cancer due to excess exposures to polychlorinated dioxins and certain PCBs. who. A landmark UN report 
assessing effects of human exposure to hormone-disrupting chemicals acknowledges that approximately 
800 chemicals are suspected to act as endocrine disruptors or mimic natural hormones or disrupt 
hormone regulation [6]. This report highlights that there are some associations between exposure to 
many of the endocrine disruptors, particularly, estrogen-mimicking chemicals and an increased risk of 
breast cancer in women. Exposure to EDCs, such as, PCBs and BPA during early development of the 
breast, endometrium, and prostate can alter their development, and possibly contribute to the 
susceptibility to diseases through effects on stem cells. 
Breast cancer and endometriosis are complex chronic diseases and they are not caused by one agent 
or one environmental factor. The majorities of the epidemiologic studies have largely focused on a single 
EDC and have ignored the possibility that multiple environmental agents may act in concert. It is 
important to consider that during the development of an individual from the single cell to prenatal stages 
to adolescent to adulthood and through the complete life span, humans are exposed to countless 
environmental EDCs. Like genes, environmental factors also interact among themselves. A single 
exposure to an EDC alone cannot explain the development of a complex chronic disease, like breast 
cancer, rather it appears that exposure to multiple EDCs across the lifespan and their interactions 
influence the development of breast cancer in an individual. A recent study from Spain lends support to 
the above concept. They have shown that the body burden of lipophilic estrogenic organohalogen 
chemicals through cumulative exposure is associated with breast cancer risks [60]. The temporal and 
spatial environmental modulations of the normal genetic and phenotypic changes in a cell lead to the 
development of a particular type of disease phenotype. However, the majority of epidemiologic studies 
measured EDC exposures later in a woman’s life, when the breast or endometrium tissue is less 
vulnerable. In-utero exposure to the estrogenic anti-miscarriage compound-diethylstilboestrol (DES) 
underlines the importance of early life EDC exposure in breast cancer development and is apparent from 
the recent report showing elevated breast cancer risks in the daughters of exposed women [61]. Given 
the proven contribution of unopposed estrogens in the development of breast cancer and endometriosis, 
it is biologically plausible that less potent EDCs may also contribute to risks of chronic diseases, such 
as breast cancer and endometriosis [59]. 
To date, most research on the endometriosis connection to breast cancer development has investigated 
only a handful of mechanisms and pathways. Genes involved in estrogen biosynthesis, metabolism, 
estrogen signaling pathway and signal transduction have been suggested to affect susceptibility of breast 
cancer and endometriosis. In our study we found that five common estrogen responsive genes, including 
CYP19A1 and ESR2 that were associated with all three EDCs-PCBs, phthalates and BPA, breast cancer, 
and endometriosis. ESR is an important molecular risk factor in the pathogenesis of breast cancer [62]. 
We examined the association of estrogen receptor ESR2 and estrogen biosynthesis enzyme, aromatase, 
CYP19A1 with endometriosis and breast cancer. Both mRNA and protein levels of estrogen receptor 2 
(ESR2) were found higher in endometriotic tissue [63]. Increased expression of aromatase has been 
found in breast tumors [64]. In women with endometriosis, elevated tissue levels of 17β-estradiol due to 
increased aromatase activity are found [65]. We also observed association of EGFR, FOS and IGF1 
genes with EDCs, endometriosis and breast cancer. Increased circulating IGF1 level is associated with 
an increased risk of breast cancer [66]. Another common gene identified in both endometriosis and breast 
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cancer in this study was stanniocalcin 2 (STC2). This is a downstream target of estrogen signaling 
pathways [67]. The expression of STC2 is induced in MCF-7 cells and the endometrial gland of women 
by 17β-estradiol and in breast tumors [68,69]. Modified expression of these genes is known to be 
involved in breast cancer pathways and include mTOR signaling pathway, focal adhesion, VEGF 
signaling pathway, and ErbB signaling pathway. However, the link of these common genes between 
these two diseases and EDCs does not prove that one causes the other. Furthermore, our study also revealed 
that PCBs and congeners 3,4,5,3′,4′-pentachlorobiphenyl (126) and 2,4,5,2′,4′,5′-hexachlorobiphenyl 
(153) are associated with some of the same estrogen receptor signaling pathway genes in breast neoplasm 
that are also observed with 17β-estradiol. Similarly, common genes of estrogen receptor signaling 
pathways were also observed with EDCs–dibutyl phthalate; diethylhexyl phthalate; and BPA and breast 
neoplasms that are also observed with 17β-estradiol. These finding support genes identified in this study 
that are highly likely to be involved in estrogen biosynthesis and estrogen signaling pathway to 
contribute to the susceptibility of breast cancer and endometriosis. 
Inflammation is another factor that appears to be common in both breast cancer and endometriosis. 
Findings of this study showed that EDCs associated with genes involved in inflammation pathways were 
also associated with 17β-estradiol in breast neoplasms. The role of estrogen in inflammation is complex. 
On one hand, studies reported suppression of inflammation with increased estrogen in animal models of 
chronic inflammatory diseases. On the other hand, estrogen has been shown to have proinflammatory 
effects in some human chronic autoimmune diseases. Estrogen induces proinflammatory cytokines,  
such as interleukin-1β (IL-1β) and tumor necrosis factor α (TNF-α), and a number of other 
inflammation associated genes [60], which were also associated with EDCs as observed in this study. 
Inflammation-mediated oxidative stress is involved in the development of both of these diseases [60]. 
Prostaglandin E2 is upregulated in endometriosis as a result of inflammation, which increases estrogen 
synthesis by up regulating aromatase. Therefore a proinflammatory milieu can also directly increase 
estrogen production and inflammation may work in conjunction with or in addition to EDCs exposure 
in the development of breast cancer in women with endometriosis [70]. 
There are several strengths of the meta-analysis of EDCs associated with breast cancer or 
endometriosis. The use of the general variance based method gave more weight to larger studies, 
considered confounding, and limited the number of studies excluded because of missing data. Most 
studies used interview data to assess exposure, providing a more direct accounting of exposure. Finally, 
the combining of similar exposure time periods and delineation of occupational and household 
agricultural/non-agricultural exposures allowed for assessment of the range of possible external 
etiological factors involved in breast cancer or endometriosis development. Limitations of the study 
include those typical of the epidemiological studies combined in meta-analyses such as publication bias, 
recall bias and exposure misclassification. In addition, EDCs and breast cancer type, along with 
individual practices of participants, were not distinguished in most studies. There are obvious limitations 
to this type of bioinformatics analyses. While this analysis generates a hypothesis for potential  
gene-EDC interactions, further research in a laboratory setting is necessary to validate their role in breast 
cancer and endometriosis. Although we carefully chose databases, at the time of writing this manuscript, 
to include comprehensive set of modified genes, we did not assess the entire set of literature on the 
development of endometriosis and breast cancer. Therefore, possibly we may have missed some 
potential modified genes in our analysis. Furthermore, epigenetic genes were not included in our analysis 
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that may have excluded other potential gene-EDC interaction pathways leading to breast cancer and 
endometriosis through these mechanisms. In spite of these limitations, this study presents a clear 
advantage in the identification of genes with potential of highly probable interactions with EDCs  
that contribute to the development of breast cancer and endometriosis. Furthermore, generation of  
gene-EDCs interaction data relevant to breast cancer and endometriosis through this integrative approach 
provides useful leads for comprehensive understanding of gene-EDCs interaction in the development 
breast cancer and endometriosis. Research with an integrated bioinformatic, biostatistic and molecular 
epidemiologic approach is however needed to study the relative contributions of PCB, phthalate and 
BPA exposure to determine the causality and progression of these complex chronic disease phenotypes 
in humans. 
In summary, the major novel findings of this study are that PCBs exposure may increase risk of  
breast cancer and endometriosis, in part, as a result of common molecular risk factors. A single exposure 
to an internal or external environmental factor alone cannot explain the development of a complex 
chronic disease, such as breast cancer and endometriosis, rather it appears that exposure to multiple 
environmental and molecular factors across the lifespan and their interactions influence the development 
of these chronic diseases in an individual. There may be common molecular risk factors between 
endometriosis and breast cancer. Given the proven contribution of unopposed estrogens to the risk for 
endometriosis or endometrial neoplasia or breast cancer, it is biologically plausible that an altered 
endogenous estrogen levels presumably from exposure to estrogen mimicking EDCs may contribute to 
the risk of these diseases. Our bioinformatics approach helps to identify genes associated with EDCs to 
generate novel hypothesis to evaluate the relationship between endometriosis and breast cancer. 
Therefore the present approach to evaluate endocrine disruptor responsiveness and their impacts on the 
biological systems is consistent with system-wide findings in breast cancer and endometriosis which 
supports this integrative idea to identify the numerous and complex modes of gene-EDCs interaction in 
these complex diseases. 
4. Methods 
The resources, workflow, meta-analysis and bioinformatics tools and integration of environmental 
epidemiologic, genomic and disease databases are shown in Figure 1. The flow chart shows the steps 
involved in identifying genes that illustrate the link between endometriosis and breast cancer based on 
environmental response on epidemiologic, genomics, and bioinformatics databases. We used the 
Comparative Toxicogenomics Database (CTD), Endocrine Disruptor Knowledge Base (EDKB) and 
KEGG database for assessing estrogenicity of environmental chemicals. 
We used EDKB computer-based models to predict affinity for binding of PCBs, Bisphenol A and 
B and phthalates to the estrogen and androgen nuclear receptor proteins, which revealed the 
estrogenic potency of each endocrine disruptor. 
We mapped environmental chemicals onto the KEGG endocrine disrupting compound, the KEGG 
pathway and metabolic pathways, particularly synthetic and degradation pathways of EDCs for assessing 
estrogenic activity. 
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4.1. Data Sources and Searches for Meta-Analysis 
A PubMed search was conducted to identify studies of the association between breast cancer or 
endometriosis and PCBs, phthalates or bisphenol A. We limited our search to studies published in the 
year 2000 and later, and articles from scholarly publications, including peer review. We identified and 
screened a total of 125 publications from which we eliminated duplicates, surveys, review articles, 
animal studies, and letters to the editor. The remaining 59 publications were then reviewed in detail for 
relevancy to our objective. Title search commands included: PCBs or polychlorinated biphenyls, 
phthalates, bisphenol A or BPA, organochlorines, and endometriosis or breast cancer. 
Study Selection: To be included in our meta-analysis, the study had to meet the following criteria:  
(1) PCBs, phthalates, or BPA had to be an exposure variable; (2) breast cancer or endometriosis had to 
be an outcome variable; (3) exposure levels reported in medians, means, geometric means, or TEQs; and 
(4) estimated odd ratios (ORs) with their 95% confidence intervals (CIs). Exclusion criteria for the initial 
search were: (1) did not report original results (reviews, comments, letters, etc.); (2) results already 
reported in another study or in a more comprehensive study; (3) geographic studies using GIS, etc.;  
(4) study had less than 4 cases in subgroup of interest; and (5) study did not report timing of exposure. 
Meta-analysis was performed and homogeneity was tested by means of the Q statistic [71]. Analysis 
was completed using Comprehensive Meta-Analysis Version 2.2.046 from Biostat, Inc., which can be 
downloaded at www.Meta-Analysis.com. 
4.2. Genomic/Bioinformatic Analyses 
We used bioinformatics approach to identify gene-EDCs interactions and diseases association as 
described previously [72]. Public databases were used for identifying estrogen mimicking endocrine 
disruptor responsive important genes with complex diseases - breast cancer or endometriosis. We used 
the following databases: 
• The Comparative Toxicogenomics Database (CTD) is located at: http://ctdbase.org/. We searched 
a list of genes found to be modulated by three selected endocrine disruptors in breast cancer or 
endometriosis. 
• The Environmental Genome Project (EGP) located at: http://www.niehs.nih.gov/research/ 
supported/programs/egp/. All “identified important genes” from the CTD database were  
included for comparison with the genes in EGP. 
• We used The Seattle SNPs database (http://pga.gs.washington.edu) to compare with the genes 
known to contain variation in breast cancer, endometriosis and exposure to individual EDC. 
• The modified genes from the CTD and environmental genome databases curation, were inputted 
into the GeneVenn program to assess their overlap as depicted in Figure 3. 
4.3. Literature Based Validation of Genes Showing Links between Endometriosis and Breast Cancer 
We investigated to validate genes that were identified using the CTD database that shows the 
biological plausibility of links between endometriosis and breast cancer. The literature and database 
search of EDC responsive genes common in both breast cancer and endometriosis lesions collected 
information on gene cellular localizations and functions, and also published research supporting the 
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genes involvement in the development of both diseases. We conducted the search on on The Human 
Gene Compendium’s Gene Cards (www.genecards.org), PubMed (www.pubmed.com), the Information 
Hyperlinked over Proteins (iHOP) Database (www.ihop-net.org), and the Epidemiologic and 
Bioinformatics Database-http://www.cdc.gov/cancer/npcr/about_inca.htm; http://cancergenome.nih.gov; 
http://www.cbioportal.org/public-portal/; http://www.endometrialdatabase.com/edb/ databases. 
We used Banjo (Duke University, NC) software for probabilistic structure learning of static  
Bayesian networks using TGCA 2012 breast cancer expression [73]. The goal of this Bayesian analysis 
was to identify critical gene-gene interactions in breast cancer to validate some of our findings of  
EDC genomics. 
In order to investigate existing literature and ontology based connections between EDC responsive 
gene lists in breast cancer and endometriosis we also conducted gene enrichment analysis. The same set 
of genes were used to produce connections that were independent of their established roles in different 
pathways. This analysis produced gene networks that included EDC responsive genes identified in this 
study from database and literature searches. According to IPA-defined significance score networks were 
ordered for Direct and Indirect Relationships, All Data Sources, All Species, and All Tissues and Cell 
Lines. This public server-based tools allow integration of pathway-related annotations from several 
public sources including Reactome, KEGG, NCBI Pathway Interaction Database, and Biocarta to 
interpret interactions among the identified set of genes. By using web-based available tools we produced 
interactive graphs linking all four EDC responsive gene lists with pathway annotations, allowing for 
graphical pathway investigation into our gene lists 
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